Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1977

Pharmacological, Behavioral and Neurochemical Assessment of
the Selectivity of the Destruction of Central Serotonergic and
Catecholaminergic Mechanisms by 6-Hydroxydopamine and
5,6-Dihydroxytryptamine in the Mouse
Frank James Cann
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Cann, Frank James, "Pharmacological, Behavioral and Neurochemical Assessment of the Selectivity of
the Destruction of Central Serotonergic and Catecholaminergic Mechanisms by 6-Hydroxydopamine and
5,6-Dihydroxytryptamine in the Mouse" (1977). Dissertations. 1723.
https://ecommons.luc.edu/luc_diss/1723

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1977 Frank James Cann

®

1978

FRANK JAMES CANN

ALL RIGHTS RESERVED

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT OF
THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6-HYDROXYDOPAMINE AND
5,6-DIHYDROXYTRYPTAMINE IN THE MOUSE.

by

Frank J. Cann

A Dissertation Submitted to the Faculty of the Graduate School
of Loyola University of Chicago in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy

September 1977

ACKNOWLEDGMENTS
Sincerest appreciation is extended to Dr. A. G. Karczmar for his continuing guidance, faith and patience.
addition, I am indebted to Dr.

v.

In

G. Longo for a stimulating

research experience and for introducing me to this exciting
field of neurotoxin research.

I am especially. appreciative

to the members of this dissertation committee and the members
of the faculty of the Department of Pharmacology for their
continuing guidance and support.
I would also like to acknowledge the patience and love
ex~ended

to me by my wife, Audrey, and her important contri-

bution in the typing of this manuscript.

The continuing

encouragement of my father, Frank Cann, and the support of
the other members of my family are also appreciated.

Mr.

Lionel Barnes is to be especially thanked for his assistance
in conducting the neurochemical assays.

Mrs. Giesla Kindel

and Mrs. Cathy Cosgrove are to be thanked for their contributions of the important assays of acetylcholine.

Final

thanks to Dr. Hoffman for his guidance in the statistical
evaluation of the data.

ii

DEDICATION

To those who love:
To those who dream:

since you bring great joy.
since you set the course of life.

iii

VITA
The author, Frank James Cann, is the son of Frank Cann
and Mary (Chernetski} Cann. He was born July 6, 1944, in
Newark, New Jersey.
His elementary education was obtained at Saint Casimir's
School of Newark, New Jersey and secondary education at East
Side High School, Newark, New Jersey, where he graduated in
1961.
In September, 1961, he entered Rutgers, The State University of New Jersey and in June, 1966, rece.ived the degrees
of Bachelor of Science and Bachelor of Pharmacy.

In September,

1967, he entered Loyola University of Chicago as a graduate
student in the Department of Pharmacology.

At this time he

was granted a National Institutes of Health Traineeship which
was renewed annually until June, 1973.

In February, 1974

he was granted the degree of Master of Science.

Since

November, 1973, he has been a senior research scientist in
the Central Nervous System Disease Therapy Section of Lederle
Labs, Pearl River, New York.
On July 5,1969 he married Audrey Joyce Vogt.

He is

the father of three children: Frank Garrett, Christine Marie
and Jennifer Lynn.
iv

TABLE OF CONTENTS
ACKNOWLEDGMENTS

................................. . ... Page
ii

DEDICATION • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

VITA

............... •· ................................

iii

iv

LIST OF TABLES •••••••••••••••••••••••••••••••••••••• viii.

LIST OF FIGURES •••••••••••••••••••••••••••••••••••••

ix

INTRODUCTION • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

1

Advantages of Neurotoxin Induced Lesions ••••••••
Methods of Administration of Neurotoxic Agents ••
Methods of Assessing the Selectivity of Neurotoxin Induced Lesions in the CNS ••••••••••••••••
Neurochemical Approaches ••••••••••••••••••••
Histological Approaches •••••••••••••••••••••
Behavioral Approaches •••••••••••••••••••••••
Pharmacological Approaches • • • • • • • • • • • • • • • • • •
The Ter.minology of Supersensitivity

1
2
4
5
10
11
20

Phenomena . . . . • • • . . . . . . . . . • . . . . • . . . . . • . . .

21

Supersensitivity of Nicotinic Receptors..
Supersensitivity of Adrenergically Innervated Smooth Muscle •••••••••••••••••••••.
Prejunctional Type ••••••••••••••••••
Postjunctional Type •••••••••••••••••
Denervation Supersensitivity • • • • • • • •
Mechanisms of Supersensitivity Development in the Periphery •••••••••••••••••••
Supersensitivity of Central Dopamine

22

Receptors • • • • . • • • • • • • • • • . . • . • • • . • • • • . • . •

23
24
25
26
27
30

Subsensitivity of Central Dopamine
Receptors • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

32

Overuse Supersensitivity of Central
Dopamine Receptors ••••••••••••••••••••••
Supersensitivity of Central NE Receptors.
Supersensitivity of Central ACh Receptors
Supersensitivity of Central Serotonin

33
34
36

Receptors • • • • • • • • • • • • • • • • • • • • • • • .. • • • • • • •

37

Demonstrating Postsynaptic Supersensitivity of Central DA and NE Receptors
With the Microiontophoretic Technique •••
Mechanisms of Supersensitivity Phenomena
in the CNS • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

v

37
40

The Approach Taken to Assess the Se.~ectivity of<
the Neurotoxicity of 6-0HDA and 5,6-0HT ••••••••

.......... . ......................... .........

METHODS
Animals and Intracerebral Injection Technique
Pharmacological and Behavioral Tests •••••••••••
Locomotor Activity ••••••••••••••••••••••••• "
Locomotor Responses to Methamphetamine
and L-DOPA •••••••••••••••••••••••••••••••••

Ever.ett Test ....•.•..•.•.....•......•..•...
Behaviora~ Response to Apomorphine •••••••••
Quantification of Tremors ••••••••••••••••••
N.eurochemical Methods ••••••••••••••••••••••••••
Extraction of the Catecholamines and

Serotonin .................... • ............ .

44

so
so
52
52
52
53

55
56
57
59

Preparation of Resin for the Elution of
Catecholamines and Serotonin •••••••••••••••
Elution of the Catecholamines and Serotonin.
Assay of Norepinephrine ••••••••••••••••••••
Assay of Dopamine ••••••••••••••••••••••••••
Assay of Serotonin •••••••••••••••••••••••••
Extraction and Assay of Acetylcholine ••••••

61
62
63
64
64

Drugs •••••••••••••••••••••••••••••.••••••••••••

67

Statistics •••••••••••••••••••••••••••••••••••••

68

...................... ..................... . .

RESULTS
Neurochemical Findings ••••••••••••••••••••••••••
s;~~()i:C)!ljLJl ••••••••

•••••••••••••••••••••••••••

Dopamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . •
Norepinephrine ............................ .
Acetycholine ...•...............•...........

Amines after L-DOPA ••••••••••••••••••••••••
Amines after 5-HTP •••••••••••••••••••••••••
Behavioral Findings ••••••••••.•••••••••••••••••••
Locomotor Activity- Single Test Procedure ••
Locomotor Activity - Repeated Test

60

69
69
69
72
73
75
75
81
84
84

Procedure ................................. .

89

Pharmacological Findings ••••••••••••••••••••••••
Locomotor Response to Methamphetamine ~
Single Test Procedure ••••••••••••••••••••••
Locomotor Response to Methamphetamine Repeated Test Procedure ••••••••••••••••••••
Locomotor Response to L-DOPA •••••••••••••••
Everett Test ...•......•.•..••••.•.••.•.••..
Everett Test after Decarboxylase Inhibition.
Response to Apomorphine ••••••••••••••••••••
Response to Tremorine ••••••••••••••••••••••
vi

90

91
93
97
100

lOS
107
110

Response to L-5-HTP ••••••••••••••••••••••••
Response of 5,6-0HT Treated Mice to L-5-HTP
after Decarboxylase Inhibition •••••••••••••

112

DISCUSSION • • • • . • • • • • • • • • • • • . • • • • • . . • • • • • • • • • • • • • • • • . .

120

Neurochemical Findings with 6-0HDA ••••••••••••••
Neurochemical Findings with 5,6-0HT •••••••••••••
Interactions Between the Dopaminergic, Cholinergic and Serotonergic Systems ••••••••••••••••••••
Pharmacological and Behavioral Results and
Their Relationship to the 5-HT, ACh and
Catecholamine Systems •• ·• • • • • • • • • • • • • • • • • • • • • • • • •
Relevance of the Effects of 6-0HDA and 5,60HT on Locomotor Activity to the Functional
State of Bioamine Systems ••••••••••••••••••
Pharmacological Assessment of CNS Function
after 6-0HDA or 5,6-0HT Treatment ••••••••••
Cholinergic System •••••••••••••••••••••
Serotonergic System ••••••••••••••••••••
Catecholaminergic System •••••••••••••••
Several Comments on the Nature of CNS Supersensitivity •.•..•..••..••....•...•.••......•....

120
122

117

124
134
134
141
144
148
152
154

SUMMARY • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

16 2

REFERENCES • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

165

vii

LIST OF TABLES
Page

Table
1. Brain Levels (in Microgm/Gm) of DA, NE and
5-HT Following Vehicle, 6-QHDA or 5,6-0HT
Trea1:ment • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

70

2. Brain Levels (in Nanom/Gm) of ACh Following
6-0HDA and 5,6-0HT Treatment ••••••••••••••••••

76

3. Brain Levels of 5-HT, DA and NE Following the
Administration of L-DOPA or 5-HT? Four Days
After Intracerebral Injection of Vehicle,
6-0HDA or 5,6-0HT •••••••••••••••••••••••••••••

78

4. Response to L-DOPA Challenge in 6-0HDA
Treated Mice .•..•.••...••••..•••.••••••••.•••.

101

5. Response to L-DOPA in 5,6-0HT or 6-0HDA
Treated Mice ••••••••••••••••••••••••••••••••••

104

6. Everett Test Scores of 6-0HDA Treated Mice
After L-DOPA and Various Doses of R04-4602

106

7. Response to Apomorphine in 5,6-0HT or 6-0HDA
Treated Mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10 8

8. Tremorigenic Response to Tremorine ••••••••••••

111

9. Tremorigenic Response to 5-HTP ••••••••••••••••

113

10. Symptornology in 5,6-0HT Treated Mice After
L-5HTP and Various Doses of R04-4602/l ••••••••

118

viii

LIST OF FIGURES
Page

Figure

1. Sagittal View of Mouse Brain Indicating Brain
Part Used for the Neurochemical Measurements ••• 58
2. Recovery of Locomotor Activity After 6-0HDA
and 5, 6-0HT-Single Test • • .• • • • • • • • • • • • • • • • • • • • • • 85
3. Regression of Locomotor Activity After Vehicle,
6-0HDA, or 5,6-0HT Treatment ••••••••••••••••••• 87
4. Locomotor Response of 6-0HDA and 5,6-0HT
Treated Animals to Methamphetamine Challenge-Single Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91

5. Regression of Locomotor Response to Methamphetamine After Vehicle, 6-0HDA or 5,6-0HT
Treatment • • • • • • • • • • • • • • • • • • • .. • • • • • • • • • • • • • • • • • .. 9 4

6. Locomotor Response to 100 Mg/Kg of L-DOPA
Following 6-0HDA and 5,6-0HT ••••••••••••••••••• 98
7. 5-HTP Tremor . . . . . . . . . • . . . . . • . . . . . . . . . . . . • . . . . . . 115

ix

INTRODUCTION

ADVANTAGES OF NEUROTOXIN INDUCED LESIONS

The physical lesioning techniques used to alter the
structure of the brain such as

radio frequency generated

heat, cutting, freezing and suctioning were rather unselective in their effects.

These aforementioned techniques

destroyed all neuronal cell bodies, dendritic arborizations, synaptic terminals and axonal projections which were
physically located at the site of the lesion.

Thus, when

the physical techniques were utilized, any post-lesion
changes in behavior could not be ascribed to the destruction of a single brain structure or a single neuronal type
as characterized by its transmitter.
Recently, a method of lesioning the brain by means of
neurotoxins came into vogue as neurotoxins with allegedly
very specific destructive effects were developed.

For

example, a neurotoxin useful for the study of dopaminergic
function should only destroy dopaminergic cells.

It was

expected that the use of such a neurotoxin would result in
readily interpretable experimental findings and that the
functional significance of the destroyed cells could be unequivocally deduced (Ungerstedt, 1973).
1

2

6-Hydroxydopamine (6-0HDA) and 5,6-dihydroxytryptamine (5,6-0HT) were two of the earliest agents claimed to
have specific neurotoxic actions on catecholamine (Ungerstedt, 197lb) and indoleamine (Baumgarten et al., 1971)
neurons, respectively.

The research reported in these

pages examines the specificity of action and certain pertinent problems concerning these two neurotoxic agents.

METHODS OF ADMINISTRATION OF NEUROTOXIC AGENTS

Neurotoxic agents may be administered peripherally
or into the brain and its ventricles, and their desired
effects may be upon either the peripheral nervous system,
the central nervous system (CNS) or both.

In the case of

6-hydroxydopamine (6-0HDA), peripheral administration results only in the destruction of the peripheral sympathetic
nerves since the compound does not pass the blood brain
barrier (Stone et al., 1962; Laverty et al., 1965; Clark et
al., 1971).

However, this peripheral selectivity is depen-

dent upon the complete development of the blood brain
barrier since brain norepinephrine (NE) can be depleted by
the systemic administration of 6-0HDA to neonatal rats
(Clark et al., 1972).

Uretsky and Iversen (1969) demon-

strated the central action of 6-0HDA after its intraventricular administration to adult rats.

3

In contrast, another neurotoxic agent, 6-hydroxydopa
{6-0HDQPA} is able to penetrate the blood brain barrier
and can induce destructive inf·luences in the periphery as
well as the CNS following its systemic administration
{Sachs and Jonsson, 1972; Jacobowitz and Kostrzewa, 1971).
However, selective lesions of the CNS, without involvement
of the periphery, were achieved by direct application of
6-0HDOPA to the CNS {Kmieciak-Kolada, et al., 1974).
Pharmacological manipulations can also alter the
actions of a neurotoxic agent. Jonsson and Sachs {1973)
demonstrated that monamine oxidase inhibition enhances the
neurotoxic action of 6-0HDOPA.

Similarly, Breese and

Traylor {1970) demonstrated that monamine oxidase inhibition markedly enhanced the dopamine depleting properties of
intracisternally administered 6-0HDA.

In contrast, the

administration of desmethylimipramine almost completely
prevented the degeneration of noradrenergic terminals by
6-0HDOPA {Jonsson and Sachs, 1973).
The route of administration can drastically affect the
selectivity of 5,6-dihydroxytryptamine (5,6-0HT); systemic
administration can result in a sympathectomy similar to that
induced by 6-0HDA Baumgarten et al., 1972d).

However, cen-

tral administration results in specific lesions of indolaminergic neurons in preference to catecholaminergic neurons
{Baumgarten et al., 1971).

4

In summary, 6-0HDA, as a neurotoxin, has been applied
centrally either intraventricularly (Barnes et al., 1973a,
b), intracisternally (Breese et al., 1970) or intracerebrally (Ungerstedt, 1973) •

The resultant destructive

effects were upon the catecholaminergic terminals, axons
and soma.

5,6-0HT, on the other hand, has been applied pri-

marily via the intraventricular route (Baumgarten et al.,
1971, 1972c; Barnes et al., 1973c; Da Prada et al., 1972;
costa et al., 1972).

METHODS OF ASSESSING THE SELECTIVITY OF NEUROTOXIN INDUCED
LESIONS IN THE CNS

It is important to emphasize the distinction between
the terms "specific" and "selective" since they are frequently used to describe neurotoxin actions.

A neurotoxin

is said to be specific if it possesses a single neurotoxic
action; that is, at all effective doses the neurotoxin in
question would be toxic to only one type of cell.

In con-

trast a neurotoxin is said to be selective when it exerts a
toxic effect upon one type of neuron at one dose, but at
another dose the neurotoxin will also exhibit toxic effects
upon several other neurons; this toxicity on several types
of neurons may exhibit a dose response relationship.

5

NEUROCHEMICAL APPROACHES

In order to assess the specificity of neurotoxin
action one would have to investigate the effects of the
neurotoxin on many neurotransmitter systems.

For example,

with the neurochemical approach one may assess the destruction induced by a neurotoxin by measuring the amount of the
neurotransmitter that would normally be present in the affected cells or nerve terminals.

Other neurochemical ap-

proaches involve the measuring of alterations in the activity of biosynthetic enzymes or in the catabolism of exogenously administered neurotransmitter, or in membrane transport mechanisms.
In the case of the cholinergic system one may determine as neurochemical parameters the levels of ACh, the

activity of acetylcholinesterase {AChE) , uptake of choline,
or the activity of choline acetyl transferase {ChAc) •

De-

creases in any of the parameters mentioned above may be
indicative of destructive influences on central cholinergic
neurons.
Similarly, if the serotonergic system was destroyed
one might expect to find decreases in the brain content of
5-HT, uptake of 5-HT or in the specific activity of tryptophan hydroxylase.

Obviously the functional biochemical

6

characteristics of the specific neurotransmitter system
involved would define the neurochemical approach to be
taken.
The following findings with 6-0HDA should give insight as to the types of neurochemical changes that could
be expected with a specific neurotoxin for catecholaminergic neurons.

Sufficient neurochemical evidence exists in

the case of 6-0HDA to indicate that destruction of central
catecholaminergic systems occurred in rats after the central administration of the compound.

For example, it was

shown that the administration of 6-0HDA lowers the brain
content of NE (Bloom et al., 1969; Uretsky and Iversen,
1969; Breese and Traylor, 1970; Scotti et al., 1971) and
dopamine (Bloom et al., 1969; Breese and Traylor, 1970;
Barnes et al., 1973b).

As the major mechanism for the

termination of central and peripheral

catecho~amine

neuro-

transmission is thought to be a rapid presynaptic uptake of
released catecholamines (Glowinski and Iversen, 1966) , it
may be expected that the destruction of catecholamine nerve
terminals should impair this uptake.

In fact, the uptake

of NE was markedly diminished in rat brain following 6-0HDA
treatment (Uretsky and Iversen, 1969; Uretsky et al., 1971).
Similar effects were observed in the periphery (Jonsson and
Sachs, 1970; Thonen, 1971).
Intraventricular administration of 6-0HDA to rats

7

significantly reduced the uptake of tritiated NE in hypothalamus and striatum but not in the pons-medulla region
(Uretsky et al., 1971).

These regional differences in up-

take of tritiated norepinephrine after 6-0HDA are postulated to indicate a greater susceptibility to destruction
of noradrenergic terminals than of noradrenergic cell
bodies by the neurotoxin (Uretsky et al., 1971).
Additionally, as a result of neurotoxin action there
may be changes in the activity of biosynthetic enzymes.

In

fact, following the 6-0HDA treatment the activity of ty-

rosine hydroxylase was markedly diminished (Breese and
Traylor, 1970).
The catabolism of neurotransmitter may also be affected by a neurotoxin, as following 6-0HDA pretreatment,
increased amounts of normetanephrine were observed after
3
exogenously administered a -norepinephrine (Uretsky and
Iversen, 1971; Breese and Traylor, 1970).

Moreover, 6-0HDA

treatment increased the formation of non-deaminated, orthomethylated metabolites by catechol o-methyl-transferase
(COMT)

(Breese and Traylor, 1970).

The increase in the

amount of o-methylated metabolites mimicked a loss of MAO
activity.

However, 6-0HDA did not alter MAO activity

(Breese and Traylor, 1970).

Thus the increase in COMT

metabolites most probably resulted from the loss of the
presynaptic uptake of NE which reduced the availability of

8

NE for deamination by MAO {Breese and Traylor, 1970).
Neurotoxins may also alter neurotransmitter turnover.
6-0HDA treatment decreased the turnover of NE {Bloom et al.,
1969; Uretsky et al., 1971).
Analogous findings with regard to the changes in the
serotonergic system were observed following 5,6-0HT treatment.

Long lasting depletions of serotonin have been re-

ported following intraventricular injections of 5,6-0HT
(Baumgarten et al., 1971; Baumgarten et al., 1972b; Bjorklund et al., 1974; Barnes et al.,
1974).

~973c;

Longo et al.,

The uptake of 5-HT was· reduced by 5,6-0HT pretreat-

ment (Daly et al., 1973).

Furthermore, the activity of the

biosynthetic enzyme tryptophan hydroxylase was also diminished following 5,6-0HT (Victor et al., 1973; Levenberg
and Victor, 1974).

Thus, a convincing case may be made

with a neurochemical approach for specific destructive effects of 6-0HDA and 5,6-0HT on the noradrenergic and serotonergic systems respectively.
However, in order to classify a neurotoxin as having
a specific action it must be demonstrated that the neurotoxin only affects a single neurotransmitter system.

In

the case of 6-0HDA, it was apparent that the compound affected both noradrenergic as well as dopaminergic nerve
terminals (Breese and Traylor, 1970; Bell et al., 1970;
Uretsky and Iversen, 1970).

In addition, 6-0HDA may affect
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rat brain 5-HT content (Bloom et al., 1969).

On the other

hand 6-0HDA had no effect on the brain content of GABA or
several other amino acids postulated to have neurotransmitter roles (Uretsky and Iversen, 1970; Jacks et al.,
1972).

6-0HDA was reported to decrease striatal acetylcho-

linesterase levels (Kim, 1973) and either to increase (Kim,
1973) or to have no effect (Consolo et al., 1974; Jacks et
al., 1972) on striatal ACh.

Thus, 6-0HDA may be able to

affect several neurotransmitter systems.

Similarly to

6-0HDA, the neurotoxin 5,6-0HT was found to have a selective rather than a specific action on brain neurotransmitter systems.

Brain NE and DA contents were lowered by

sufficiently high doses of 5,6-0HT (Bjorklund et al., 1974;
Baumgarten et al., 1972b).
Thus, it is probably more correct to speak of neurotoxin selectivity rather than specificity.

That is, until

proven otherwise, one should assume that a neurotoxin does
not affect a single neurotransmitter system (i.e. is not
specific); however, the neurotoxin may be more effective
with respect to one neurotransmitter system as compared to
another (i.e.-it'may be selective).

The degree of neuro-

toxin selectivity would be dependent primarily upon the
degree of separation that would exist between the effect on
one system versus another.

These preceding statements are

in essence a restatement of a basic pharmacological con-
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cept; that drugs affect many biological systems and generally are selective rather than specific in their actions.

HISTOLOGICAL APPROACHES

Histological and histochemical examination of the
brain and specific pathways, the neurotransmitter composition of which is known, is an extremely valuable tool in
determining the extent of neurotoxin induced neuronal damage.

A histochemical fluorescence technique is available

to localize the catecholamines and indoleamines within the
brain (Dahlstrom and Fuxe, 1964).

This technique has been

methodically applied to illustrate the cellular sequelae
of the central administration of either 6-0HDA or 5,6-0HT.
The histological changes induced by 6-0HDA were
similar in the periphery and in the CNS.

In the periphery,

6-0HDA produces visible evidence of adrenergic nerve terminal degeneration (Tranzer and Thoenen, 1968).

Centrally

administered 6-0HDA also produces visual signs of neurotoxicity to NE and DA terminals and DA cell bodies (Ungerstedt, 197lb; Bloom et al., 1969).

Similarly, microscopic

and histochemical studies of neurons after 5,6-0HT have
yielded visual evidence of destruction of noradrenergic
terminals in the periphery (Baumgarten et al., 1972d) while
in the CNS both 5-HT terminals (Baumgarten and Lachenmayer,
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1972; Baumgarten et al., 1972c) and axons (Baumgarten,
l972a) show visible evidence of destruction after 5,6-0HT.
Histological and histochemical analysis allows for a
simultaneous evaluation of neurotoxin induced destruction
of the target as well as non-target structures.

Such an

examination would be difficult if not impossible with the
neurochemical approach.

However, the approaches are com-

plementary and taken together provide the strongest evidence for specificity and/or selectivity of the neurotoxin
action.

BEHAVIORAL APPROACHES

Present day neuroscience demands the determination of
the relevance of experimentally induced neurochemical and
histological changes, particularly by means of investigations of behavioral correlates of the induced neurochemical
or histological changes.

It became apparent from such in-

vestigations that many behaviors have a multitransmitter
basis.

Thus, the behavioral effect of a neurotoxin cannot

be readily ascribed to its action on a specific neurotransmitter system, till its action on other neurotransmitter
systems can be excluded.
The biogenic amines have been implicated as modulators of many behaviors, and the behavioral correlates of
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the action of the neurotoxins 6-0HDA and 5,6-0HT have been
extensively investigated.

In most cases the effects of

these neurotoxins have supported the concept of a modulatory role of the biogenic amines in several behaviors;
examples of the behavioral sequelae of the actions of 60HDA and 5,6-0HT are adduced below.

It will become ap-

parent on the basis of these examples that the question of
selectivity of action of either 6-0HDA or 5,6-0HT has not
been thoroughly investigated by means of the behavioral
approach; in most cases, there are no data sufficient to
correlate a specific neurochemical effect with the behavioral action.
One pertinent example concerns the avoidance response.
The catecholamines have been implicated in avoidance responding for many years as the neuroleptics were found to
be capable of inhibiting this response (Hanson et al.,
1966) •

A cholinergic component was also implicated since

anticholinergic agents reversed the block of avoidance induced by dopamine blocking agents (Hanson and Stone, 1964;
Fibiger and Phillips, 1974).

In addition, a modulatory

role for serotonin has been suggested from genetic studies
(Oliverio et al., 1974).

Yet, 6-0HDA studies suggest that

NE may not be needed for avoidance.

Indeed, stereotaxic

injections of 6-0HDA into the tegmental area containing the
NE ascending fiber tracts did not impair the acquisition of
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avoidance (Cooper et al., 1974).

However, stereotaxic 6-

0HDA injections which involved the ascending dopaminergic
fiber bundles, or terminals in the caudate-putamen, resulted in a marked inhibition of acquisition (Cooper et al.,
1974).

Similar results were observed by Fibiger et al.

(1974) who reported an impairment in the acquisition of one
way active avoidance in rats pretreated with 6-0HDA.
A similar situation occurs with regard to the "reward
system".

While these data may indicate that 6-0HDA exerts

a specific dopaminergic rather than a noradrenergic effect
on avoidance, the literature dealing with this matter is
controversial, and the question is not settled.
work by Stein et al.

Previous

(1968) employing the intracranial self

stimulation technique resulted in a noradrenergic theory of
reward; that is, noradrenaline was proposed to be the neurotransmitter required for self stimulation.

Recently,

6-0HDA has been used to support this concept (Stein, 1971) •
After 6-0HDA both the brain norepinephrine content and the
self stimulation rate were decreased (Stein, 1971).

How-

ever, other investigators rejected a modulatory role of
norepinephrine in self stimulation; since after 6-0HDA,
they were able to initiate normal rates of self stimulation
in spite of significant reductions in brain NE (Antelman
et al., 1972).

Furthermore, a facilitatory modulatory role

for DA was proposed, when the intraventricular administra-
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tion of haloperidol, a dopamine receptor blocker, significantly suppressed the rate of self stimulation (Lippa et
al., 1972).

Moreover, the identification of other modula-

tory neurotransmitters complicates the analysis of this
behavior.

For example, an inhibitory modulatory role for

the serotonergic syst·em has also been suggested to be an
important regulator of intracranial self stimulation, i.e.
reward behavior (Peschel and Ninteman, 1971).
The biogenic amines have also been implicated in
nocioception.

A serotonergic mechanism has been implicated

in morphine analgesia (Tenen, 1968).

It was found, using

the flinch-jump method of Evans (1961) that the tryptophan
hydroxylase inhibitor, parachlorophenylalanine (PCPA; Koe
and Weissman, 1966) inhibited the analgesic effect of morphine.

These data were supported by the fact that PCPA or

a lesion of the median forebrain bundle which depleted
brain 5-HT, increased the animal sensitivity to pain, without also increasing the animals' generalized responsiveness
to a puff of air (Harvey and Yunger, 1973).

However, these

later investigators could not alter morphine analgesia by
either method and concluded that morphine analgesia is not
modulated by 5-HT (Harvey et al., 1974).

In contrast,

lesions of the midbrain raphe nuclei did not affect pain
sensitivity but abolished the analgesic effect of morphine
(Pepeu et al., 1974a). The lesions of the midbrain raphe
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in addition to depleting brain 5-HT also decreased ACh
content in the telendiencephalic portion of rat brain.

The

picture is further complicated by the fact that PCPA also
depletes brain norepinephrine content (Miller et al.,
1970), and MFB lesions deplete dopamine as well as NE content (Harvey et al., 1974).

Thus, we are still at a con-

troversial stage in the understanding of the role of neurotransmitters in pain sensitivity and drug induced analgesia.

Selective neurotoxins may aid our understanding in

this area.
Still another example illustrating the difficulty in
relating a behavior to a specific neurotransmitter concerns
aggression.

The serotonergic system has been implicated in

aggressive behavior but not without confounding influences
from other neurotransmitter systems.

Muricidal rats appear

to have an alteration of serotonergic activity (Di Chiara
et al., 1971) but an interaction with ACh can not be excluded in this behavior because o·f its induction by chronic
dosing of pilocarpine (Haubrich and Reid, 1972; Vogel and
Leaf, 1972).

Similarly, in the case of isolation induced

aggression in the mouse, it has been suggested that the decreased turnover in serotonergic as well as catecholaminergic neurons may be necessary (Valzelli, 1974).

Thus,

assessment of neurotoxin selectivity with this procedure
would not be meaningful without a neurochemical analysis of
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all the neurotransmitter systems involved.
The sexual behavior of male rats was found to be
modulated by several biogenic amines.

The sexual behavior

of male rats was inhibited by activity of the serotonergic
system (Tagliamonte et al., 1969).

However, as PCPA has no

effect on the sexual activity of cats, the general applicability of a serotonergic concept has been questioned
(Zitrin et al., 1970).

Furthermore, the sexual behavior of

the rat may also be modulated by a dopaminergic facilitatory mechanism (Gessa and Tagliamonte, 1974).

The use of

the neurotoxin 5,6-0HT supports the serotonergic involvement in sexual behavior since after its administration a
hypersexual response is induced (Da Prada et al., 1972).
On the other hand, the failure to decrease the facilitatory
effect of 5,6-0HT by means of 6-0HDA suggests that some additional clarification regarding the postulated facilitatory role of dopamine is indicated (Da Prada et al., 1972).
Locomotor activity has also been suggested to have a
multineurotransmitter basis.

There is much evidence to

suggest that the central catecholaminergic system provides
a facilitatory modulation of locomotion.

Evidence for a

relationship between central catecholamines and the locomotion was provided by the early work with reserpine.

Re-

serpine treatment depressed locomotion and decreased the
brain content of norepinephrine of rats (Holzbauer and
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vogt, 1956).

However, reserpine also depleted serotonin

and the remarkable behavioral depression which ensued was
ascribed to a central
1959).

re~ease

of serotonin (Brodie et al.,

The demonstration that a good correlation existed

between reserpine induced locomotor depression and catecholamine depletion tended to refute the serotonergic hypothesis (Carlsson, 1961; Matsuoka et al., 1964).

Additional

support for a direct involvement of catecholamines was obtained by the discovery that L-DOPA effectively reversed
the reserpine depression while 5-HTP did not (Blaschke and
Chrusciel, 1960; Carlsson et al., 1957).
The role of the catecholamines in locomotor behavior
became more firmly established with the discovery of alphamethylparatyrosine

<~-mpt),

a compound which inhibits

tyrosine hydroxylase, and selectively depletes brain catecholamines without altering brain 5-HT levels (Weissman,
1965) •

The locomotor depression induced by alpha-methyl-

paratyrosine was consistent with the locomotor stimulation
induced by amphetamine, primarily a releaser of catecholamines (Moore et al., 1970). Furthermore, the stimulant
actions of amphetamine were reported to be blocked by
alpha-methylparatyrosine (Weissman, 1966; Rech, 1970); this
fact further supported the role of catecholamines in locomotor behavior.

L-DOPA, which does not require the action

of tyrosine hydroxylase to form catecholamines, was able to
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reverse the

~-mpt

and Rech, 1967).

induced depression of locomotion (Moore

Altogether, these data suggest a strong

facilitatory effect of catecholamines on the locomotor behavior of the rodent.
The results obtained with a potent dopamine-p;' hydroxylase inhibitor, FLA-63, which blocked the synthesis
of norepinephrine from dopamine suggested an involvement of
NE in locomotion, as FLA-63 produced a reduction in locomotor activity at doses which depressed the brain content
of NE (Svensson and Waldeck, 1969).

Furthermore, the loco-

motor stimulant effect of L-DOPA was antagonized by FLA-63
(Stromberg and Svensson, 1971).

Finally, the FLA-63 in-

duced depression of locomotor activity was reversed by a
monamine oxidase inhibitor (Svensson, 1970).
Studies with the centrally acting
agonist, clonidine and the

~-receptor

~-receptor

antagonist, phenoxy-

benzamine also implicated norepinephine, a long recognized
o(-receptor agonist, as a facilitatory modulator of locomotion.

Spinal cats were stimulated into active coordinated

locomotor movements by clonidine (Forssberg and Grillner,
1973).

A central blocking activity was demonstrated for

phenoxybenzamine in spinal cats (Anden et al., 1967).

Fi-

nally, clonidine enhances the locomotor stimulation induced
by apomorphine following reserpine (Anden and Strombom,
1974) •

This stimulation of locomotion by clonidine was
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antagonized by phenoxybenzamine (Anden and Strombom, 1974) •
In addition, the cholinergic system may also contribute an inhibitory modulation of locomotion.

The cho-

linergic modulation may be indirect through an influence
on the catecholaminergic system.

Indeed, the locomotor

stimulation induced by muscarinic blocking drugs is dependent upon an intact catecholaminergic system (Thornburg
and Moore, 1973a, b).
The exact nature of the modulatory role of serotonin
in locomotor behavior is still controversial.

For example,

a facilitatory modulation of locomotion by serotonin has
been postulated to be independent of the catecholamines
(Modigh, 1974).

In contrast, a serotonergic inhibition of

catecholamine induced stimulation of locomotion has also
been postulated (Mabry and Campbell, 1973).

Further re-

search will be needed to clarify the role of serotonin in
this behavior •.
6-Hydroxydopamine treatment has been shown to induce
a transient decrease in locomotor activity (Breese and
Traylor, 1970; Scotti de Carolis et al., 1971).

Similarly,

5,6-0HT has also been shown to depress locomotor activity
of rodents (Barnes et al., 1973c; Longo et al., 1974).
Thus, the neurotoxins' effects on locomotor behavior support the concept of a modulatory role of the bioamines in
this behavior.
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In conclusion, it is apparent that 6-0HDA and 5,6-0HT
have dramatic influences on behavior.

Moreover, because of

the multineurotransmitter basis of the behaviors studied,
the behavioral effects of 6-0HDA or 5,6-0HT treatments cannot stand alone as an argument for neurotoxin specificity
or selectivity.

PHARMACOLOGICAL APPROACHES

The proof of neurotoxin selectivity by means of the
pharmacological approach primarily depends upon the demonstration of selective changes in the responsiveness of the
organism to drugs i.e. changes in the drug-receptor interaction.

It may be expected that the pharmacological changes

induced by a neurotoxin induced lesion of the brain should
resemble those induced by physical induced lesions.

These

changes frequently take the form of a supersensitivity,
though a subsensit.ivity may also develop.

al~

Thus, one may

use the presence of either supersensitivity or subsensitivity to a specific agonist as a marker of the damage to a
biological system which is normally affected by that
agonist.

This present investigation in part, explored the

extent that supersensitivity or subsensitivity would reveal the nature of the neurotoxicity induced by 6-0HDA or
5,6-0HT.
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At the time of this investigation very little was
known about the nature of supersensitivity in the nervous
system.

Most of our knowledge about supersensitivity was

derived from investigations of the denervation phenomena
at the periphery.

Therefore, supersensitivity phenomena

at the peripheral level will be described to characterize
their nature and to provide the implications for the
studies of the selectivity of neurotoxin action in the CNS.

THE TERMINOLOGY OF SUPERSENSITIVITY PHENOMENA

Lesions of the nervous system can induce changes in
the innervated structure's responsiveness to agonists.

The

change usually takes the form of an enhanced response.

The

term "denervation supersensitivity" was used to describe
this phenomenon.

Cannon and Rosenbluth (1949) indicated

that the phenomenon was recognized as early as 1880 by
Claude Bernard.
The phenomenon of denervation supersensitivity is
demonstrable when a denervated tissue becomes more responsive than normal to its physiological neurotransmitter;
supersensitivity should also result in an increased response
of the tissue to agonist agents which mimic the action of
the neurotransmitter.
Interestingly, it has recently been demonstrated that
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denervation per ·se was not a prerequisite for the development of supersensitivity.

Basically, it was discovered

that a reduction in either the prejunctional content of the
physiological neurotransmitter or in the rate of the prejunctional neuronal impulses was sufficient to induce
supersensitivity.

This supersensit.ivity which did not re-

quire denervation was termed "disuse supersensitivity".
As a result of numerous investigations, several types
of supersensitivity have been described.

Terms such as

"prejunctiona;t.", "postjunctional", "decentralization",
"deviation", "denervation", "disuse", "presynaptic", "postsynaptic", "cocainelike" and "nondeviation" have been used
to describe these varied forms of supersensitivity.

The

aforementioned terms resulted primarily from investigations
of supersensitivity in the periphery.

It is probable that

the list may become even more extensive as more knowledge
about the nature of supersensitivity in the central nervous
system is obtained.

SUPE'RSENS:I'TIVI'TY' OF NICOTINIC RECEPTORS

Supersensitivity is a complex subject as there is no
universal mechanism to account for the development of
supersensitivity even within one class of receptor.

For

example, vari.ous structures which contain nicotinic choli-
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nergic receptors display different responses towards denervation.
Striated muscle contains a nicotinic cholinergic
receptor and exhibits supersensitivity to acetylcholine
following denervation.

The supersensitivity of denervated

striated muscle is not specific to acetylcholine.

The

denervated skeletal muscle also exhibits supersensitive responses to caffeine, potassium and epinephrine as well as
acetylcholine (Cannon and Rosenbluth, 1949).

In contrast

a different response is observed following denervation of
a sympathetic ganglion which also contains a nicotinic
cholinergic receptor.

Preganglionectomy of the sympathetic

ganglion innervating the cat nictitating membrane apparently results in a subsensitivity of the nicotinic cholinergic receptor within that ganglion but strangely a supersensitivity of the muscarinic receptor (Dun et al., 1976) as
well as the nictitating membrane (Sharpless, 1975).

SUPERSENS:ITIVITY OF ADRENERGICALLY INNERVATED SMOOTH MUSCLE

The phenomenon of supersensitivity of smooth muscle
and its catecholamine receptors appears to be even more
complex than that of the nicotine receptors in striated
muscle and the ganglion.

Many of the terms used to de-

scribe supersensitivity phenomena are a direct result of
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research on supersensitivity in smooth muscle.

In contrast

to the somatic nervous system, the denervation supersensiti vi ty which occurs in adrenergically inne.rvated smooth
muscle of the autonomic nervous system may be pre.junctional
as well as postjunctional (Trandelenburg, 1966).

The terms

"pre.junctional and postjunctional supersensitivity" refer
to a mechanism involving the prejunctional neuronal and
postjunctional smooth muscle side of the neuromyal junction, respectively.

The presence of both types of super-

sensitivity in smooth muscle occurs only in the case of a
postganglionectomy, while in the case of a preganglionectomy only the postjunctional type occurs (Trandelenburg,
1966).

PREJUNCTIONAL TYPE

The prejunctional type of supersens.itivity occurs
soon after denervation and appears to be rather specific to
norepinephrine.

Moreover, as a rapid reuptake mechanism

exists in the adrenergic nerve terminals and functions as
the major mechanism for the termination of action of synaptically released norepinephrine (Glowinski and Iversen,
1966)

~

any impairment of this reuptake mechanism would al-

low the synaptically released or exogenous NE to interact
with the postsynaptic receptor for a prolonged period of

25

time.

The net result of impaired reuptake would be to

enhance the agonist action of a fixed amount of NE

and to

reduce the effective agonist concentration of exogenous NE.
Thus, the loss of a presynaptic uptake process would result
in a supersensitive response.

Thus, the mechanism of pre-

junctional supersensitivity is thought to be due to the
loss of the reuptake mechanism for liberated catecholamines
by the degenerating nerve terminal.

The term "cocaine-

like supersensitivity" has been used as a synonym for the
prejunctional type of supersensitivity as cocaine will
block the uptake of NE by the catecholaminergic nerve terminals (Trandelenburg, 1966).

POSTJUNCTIONAL TYPE

The postjunctional type of supersensitivity in
adrenergically innervated smooth muscle develops slowly and
is not as specific as the prejunctional type.

The smooth

muscle develops a supersensitive response to acetylcholine,
potassium ion and to norepinephrine.
Another term applied to the postjunctional type of
supersensitivity is "decentralization type".

It is in

reference to decentralization that the term "disuse supersensitivity" developed.

The concept of disuse was employed

in pharmacological investigations in which reserpine was
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utilized to deplete the neuron of norepinephrine and to
induce a state of diminished rather than totally absent
neuronal function.

It was apparent that the type of super-

sensitivity which developed after reserpine, disuse, decentralization, or other procedures which diminished the
flow of neuronal impluses to the adrenoceptive neuroeffector, mimicked that of the postjunctional type as it exhibited a long latency and a lack of specificity (Westfall,
1970) •

DENERVATION SUBSENSITIVITY

Besides the development of supersensitivity, a subsensitivity to pharmacological agents may also develop.
Subsensitivity may develop as a change in the agonist receptor site following extended periods of activation.

For

exarnple,the number of beta adrenergic receptors in frog
erythrocytes was markedly reduced following a 24 hour exposure to isoproterenol or norepinephrine (Mukherjee et
al., 1975).

Moreover, denervation subsensitivity to in-

direct acting agonists may occur as the latter depend for
their action upon both an intact nerve terminal and normal
supplies of releasable neurotransmitter (Flechenstein and
Burn, 1953) •
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MECHANISMS OF. SUPERSENSITIVITY DEVELOPMENT 'IN THE PERIPHERY

Varied mechanisms have been suggested for the development of supersensitivity in the periphery.

One mechanism

suggested for the induction of supersensitivity in striated
muscle was the loss of a trophic factor from the nerve.
This concept received less emphasis in recent times since
it was demonstrated that exercising a denervated muscle
with either electrical stimulation (Lome and Rosenthal,
1972} or via acetylcholine (Drachman and Witzke, 1972} was
sufficient to prevent the development of supersensitivity.
Any trophic influence therefore, must reside within the
muscle itself and may not be a result of a trophic factor
released from the nerve terminal.

The mechanism of this

supersensitivity appears to be a proliferation of cholinoceptive sites outside of the junctional area (Axelsson and
Thesleff, 1959}.
In sympathetically innervated smooth muscle the mechanism for the development of supersensitivity of the prejunctional type has been shown to be due to the loss of the
catecholamine reuptake mechanism of the nerve terminal
(Trandelenburg, 1966}.

In contrast, evidence is still be-

ing accumulated to characterize the mechanism for the development of supersensitivity of the postjunctional type.
Fleming et al.

(1975} demonstrated a partial depolariza-
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tion, on the order of lOmv., in smooth muscle that exhibited supersensitivity of the postjunctional type.

Further-

more, since no changes were observed in the junctional potentials, it was concluded that there were no changes in
the postjunctional receptors (Fleming et al., 1975).

More-

over, acute depolarization of this tissue results in an
acutely developing supersensitivity similar to that observed after decentralization (Fleming et al., 1975).

Thus,

depolarization may play an important role in the postjunctional supersensitivity of sympathetically innervated
smooth muscle.

In addition, the postsynaptic type of

supersensitive response of smooth muscle to potassium,
acetylcholine and calcium are dependent upon the presence
of calcium ion in the external tissue fluid (Carrier,
1975).

In contrast, the supersensitive response of the

same tissue to catecholamines was independent of external
calcium concentration (Carrier, 1975).

Morphologically,

an increase in the number of nexial contacts was observed
after postganglionic denervation of the vas deferens (Westfall et al., 1975).

It was also suggested that an increase

in ATP parallels or precedes the development of postsynaptic supersensitivity in denervated tissues (Westfall et
al., 19 75) •
A novel mechanism was recently suggested to explain
the hydrocortisone induced supersensitivity of the nicti-
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tating membrane to catecholarnines.

Trandelenburg and

Graefe (1975) demonstrated that inhibition of catechol-amethyl transferase (COMT) induces supersensitivity of the
cat nictitating membrane in a highly specific manner.

The

effect is limited to the response to NE, the physiological
neurotransmitter, and only after the reuptake mechanism of
the presynaptic terminal has been impaired either by denervation or cocaine.

The hydrocortisone induced supersensi-

tivity possessed characteristics similar to that induced by
a COMT inhibitor.

It was suggested that, hydrocortisone

induced supersensitivity by blocking the high affinity uptake of NE into the high affinity methylation compartment,
within which released catecholamines are actively being
methylated by COMT (Trandelenburg and Graefe, 1975).
There are several conceivable mechanisms for the development of supersensitivity in a cholinergic junction.
Examples of these mechanisms are: a loss in junctional cholinesterase content or activity, an increase in the amount
of acetylcholine released per impulse

and an increase in

the responsiveness of the receptor to activation by ACh.
It is interesting that the apparent mechanism for the development of supersensitivity in denervated striated muscle
is the proliferation of extrajunctional cholinergic receptors (Axelsson and Thesleff, 1959).
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SUPERSENSITIVITY OF CENTRAL DOPAMINE. RECEPTORS

In contrast to the peripheral somatic and autonomic
nervous systems, relatively few studies were reported which
suggested the development of supersensitivity within the
brain; most studies were primarily concerned with the dopaminergic system, and employed prolonged reductions of brain
dopamine content to induce the supersensitivity.

This ap-

proach was analogous to disuse supersensitivity in the
periphery.

Stalk and Rech (1967) utilized chronic reser-

pine treatment to reduce brain dopamine content; the treatment led to the development of a supersensitive locomotor
response to d-amphetamine, a dopamine releasing agent.
Similarly, a prolonged dopamine depletion was induced by
the dietary administration of

o<... -methylparatyrosine, and it

resulted in a supersensitive locomotor response to ephedrine (Dominic and Moore, 1969).

Similarly, the prolonged

reductions in rat brain dopamine induced by 6-0HDA also
resulted in a supersensitive response to the dopamimetics,
apomorphine and L-DOPA (Ungerstedt, 197la; Uretsky and
Schoenfeld, 1971) •
More recently, other laboratories have verified the
induction of dopaminergic receptor supersensitivity induced
either by ol-mpt, reserpine or 6-0HDA treatment (Friedman
et al., 1976; Nahorski, 1975; Tarsy and Baldessarini, 1974;
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Thornburg and Moore, 1975).

Furthermore, persistent or

acute blockade of dopaminergic receptors with neuroleptic agents also induced dopaminergic receptor supersensitivity {Christensen et al., 1976; Jackson et al., 1975;
von Voigtlander et al., 1975; Yarbrough, 1975).

Agonist

activation by L-DOPA of dopamine receptors during the
period of

~-mpt

treatment prevented the development of

supersensitivity by

~-mpt

(Gudelsky et al., 1975).

Supersensitivity of "dopaminergic autoreceptors" is
another related phenomenon.

Dopamine receptors have been

postulated to exist on the dopaminergic neuron; hence,
they were called autoreceptors (Bunney and Aghajanian,
1975).

The dopaminergic autoreceptors have been postulated

to be responsible for the suppression of firing by dopamimetic agents of dopaminergic cells in the substantia nigra
(Bunney and Aghajanian, 1975); the inhibition of dopamine
turnover by apomorphine was also thought to be the result
of the activation of dopaminergic autoreceptors (Roth et
al., 1975).

Chronic haloperidol treatment reduced the

threshold dose of apomorphine required to reduce the turnover of dopamine; this effect may be an example of supersensitivity of the dopaminoceptive autoreceptors {Gianutsos
et al., 1975).

Moreover, the presence of presynaptic re-

ceptors may modulate the degree of supersensitivity evidenced by postsynaptic dopamine receptors.

The evidence
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for the modulation of postsynaptic receptor supersensitivity by presynaptic dopamine receptors was provided by
the enhancement of reserpine-elicited dopaminergic supersensitivity by repeated administration of apomorphine or
~-methyl-p-tyrosine

during the reserpinization (Friedman

et al • , 19 76 ) •

SUBSENSITIVITY OF CENTRAL DOPAMINE RECEPTORS

Subsensitivity of dopaminergic receptors has also
recently been suggested to occur.

Apomorphine administra-

tion induced a hypothermic response in rodents; this response was characterized by acute desensitization, as a
single dose of apomorphine prevented subsequent doses of
apomorphine from inducing hypothermia (Costentin et al.,
1975b}.

The response was specific for dopamine receptors

since the hypothermic responses to clonidine, oxotremorine
and promethazine were not altered by prior treatment with
apomorphine (Costentin et al., 1975b).

Chronic haloperidol

induced supersensitivity to the apomorphine induced hypothermia (Costentin et al., 1975a).

In contrast, 6-0HDA

treatment induced a subsensitivity to the hypothermic response to apomorphine (Costentin et al., 1975a}.
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OVERUSE SUPERSENSITIVITY OF CENTRAL DOPAMINE RECEPTORS

In addition to the concept of disuse supersensitivity, recent experimental findings have suggested the development of overuse supersensitivity in central dopaminergic systems (Klawans and Margolin, 1975) •

The adminis-

tration of amphetamine on a chronic basis and in high doses
produced an enhanced response to amphetamine and apomorphine (Klawans and Margolin, 1975).

It was suggested that

L-DOPA induced dyskinesias, amphetamine choreatic movements
and amphetamine psychosis may be a result of supersensitivity of dopaminergic receptors induced by their chronic
excessive stimulation.

The exact mechanism and implica-

tions of these findings remain obscure at present.

More-

over, certain other amphetamine related phenomena must be
excluded before overuse supersensitivity can be considered
as a separate phenomenon. For example, amphetamine also
produces supersensitivity of adrenergically innervated tissue in the periphery; this has been classified as the presynaptic type of supersensitivity, being due to amphetamine's blockade of uptake of NE by the adrenergic neuron
(De Moraes and Carvalho, 1971).

It is doubtful that block-

ade of the presynaptic NE uptake mechanism by amphetamine
could account for the development, after chronic amphetamine treatment, of a supersensitive response to apomor-
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phine, since apomorphine does not depend upon presynaptic
stores of catecholamines for its action (Ernst, 1967,
1969).

There also exists the problem of state dependency

and drug conditioning phenomena which may mimic the development of supersensitivity (Tilson and Rech, 19'73}.

Fur-

thermore, chronic amphetamine treatment may induce dopaminergic receptor supersensitivity via a chronic catecholamine depletion (Lewander, 1974; Tonge, 1974).

Thus,

the mechanism of amphetamine induced supersensitivity of
central dopamine receptors remains to be placed in proper
perspective with the other known effects of chronic amphetamine administration.
In contrast, chronic amphetamine treatment may induce
in the periphery a subsensitivity of noradrenoceptors which
is evidenced as a decreased elevation of cyclic AMP by
noradrenaline.

The subsensitivity appeared to be specific

since the cyclic AMP elevations induced by either dopamine,
5-HT or adenosine remained unaffected by the chronic amphetamine treatment (Martres et al., 1975).

Chronic amphetamine

treatment has not yet been observed to induce receptor subsensitivity in the CNS.

SUPERSENSITIVITY OF CENTRAL NE RECEPTORS

In addition to the studies on dopamine receptor
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supersensitivity some investigations have been concerned
with demonstrating the supersensitivity of central noradrenergic receptors.

These studies employed the technique

of depletion of brain NE content to induce a disuse type
of supersensitivity.
thermic response to

For example, a supersensitive hypoc~onidine

was observed in. rats three

months after 6-0HDA induced lesions of the ascending NE
containing pathways (Zis and Fibiger, 1975).
In another study, treatment with reserpine was reported, after 24 hours, to induce a supersensitive response
of brain stem neurons to microiontophoretically applied
norepinephrine (Boakes et al., 1971).

Although an effect

similar to that of reserpine was expected neither the
dopamine-~-hydroxylase inhibitor, FLA-63, nor the tyrosine

hydroxylase inhibitor,«-mpt, were able to induce changes
in brain stem neuronal firing rates (Boakes et al., 1971).
Furthermore, a presynaptic as well as postsynaptic
norepinephrine receptor supersensitivity has been suggested
to occur in rat cerebral cortical slices following intraventricular 6-0HDA treatment (Kalisker et al., 1973; Huang
et al., 1973).

An acute short lasting subsensitivity and

longer lasting supersensitivity to NE has been described
following reserpine (Palmer et al., 1975).

A beta-adrener-

gic receptor has been described in the rat pineal gland
which regulates the activity of N-acetyltransferase and
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therefore the degree of melatonin synthesis (Brownstein et
al., 1973).

Supersensitivity of the pineal !'-adrenergic

receptors has been demonstrated following denervation via
a superior cervical ganglionectomy (Deguchi and Axelrod,
1972), disuse via constant light, reserpinization or 6-0HDA
treatment (Deguchi and Axelrod, 1973; Weiss and Strada,
1972).

Thus, supersensitivity of central noradrenergic

catecholaminergic receptors has been demonstrated in a
number of ways which primarily rely upon a diminution in
the amount of stimulation of the catecholaminergic receptors.

SUPERSENSITIVITY OF CENTRAL ACh RECEPTORS

In contrast to the numerous investigations of supersensitivity in the peripheral somatic and autonomic nervous
systems, there are relatively few examples of supersensitivity of the cholinoceptive neurons of the central nervous
system.

Chronic scopolamine administration induced a

su~

persensitive hypothermic response to pilocarpine (Friedman
et al., 1969).

More directly, Bird and Aghajanian (1975)

demonstrated a supersensitive response of cholinoceptive
hippocampal pyramidal cells to acetylcholine following the
destruction of a cholinergic input from the medial septal
nucleus.

Clinically, it has been suggested that the par•
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kinsonian patient exhibits a supersensitivity to cholinergic agents; however, this supersensitivity has been suggested to be due secondarily to the loss of dopaminergic
input to the striatum (Weintraub and Van Woert, 1975).
Evidence for a subsensitivity of central cholinergic
receptors has also been accumulated.

Tolerance develops to

the disruptive effects of diisopropylflurophosphate (DFP)
on fixed ratio (FR) responding; a hyposensitivity of cholinergic mechanisms has been postulated to account for the
development of this tolerance (Russell et al.,l975).

More-

over, chronic dopaminergic blockade with haloperidol decreased the locomotor depressant action of pilocarpine.
This has been suggested to be an example of central cholinergic receptor subsensitivity (Gianutsos and Lal, 1976).

SUPERSENSITIVITY OF CENTRAL SEROTONIN RECEPTORS

The advent of investigations into supersensitivity of
central serotonin receptors began with the use of 5,6-0HT
(Barnes et al., 1973c; Longo et al., 1974), (cf. Discussion).

DEMONSTRATING POSTSYNAPTIC SUPERSENSITIVITY OF CENTRAL DA
AND NE RECEPTORS WITH THE MICROIONTOPHORETIC TECHNIQUE
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Although the.re exists much indirect evidence suggesting postsynaptic receptor supersensitivity in the central
nervous system, it has not been unequivocally demonstrated
by a direct technique.

The direct method for the demon-

stration of supersensitivity to a neurotransmitter in the
central nervous system involves the use of the microiontophoretic application of that neurotransmitter to its
receptive cells.

The major difficulty with the ionto-

phoretic technique in the central nervous system is that
one can never be certain whether an observed response is
the direct result of an interaction of the iontophoresed
neurotransmitter with the postsynaptic receptor or whether
it is the indirect result of an interaction of the iontophoresed neurotransmitter with receptors on the presynaptic
boutons which impinge upon that cell.

This difficulty is

primarily a result of the presence of a large number of
synaptic contacts which impinge upon cells in the mammalian
central nervous system.

Thus,it would be difficult to dis-

tinguish presynaptic from postsynaptic forms of supersensitivity in the CNS with this technique.
These practical difficulties with the microiontophoretic technique were observed recently in the course of
the attempts to demonstrate postsynaptic receptor supersensitivity of central dopaminoceptive cells.

The microion-

tophoretic application of dopamine to cells in the stria-
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tum, following dopamine depleting lesions, resulted in the
description of both a subsensitivity as well as a supersensitivity to dopamine.

Spehlmann and Stahl (1974) reported

a subsensitivity of dopaminoceptive cells in the corpus
striatum following tegmental lesions in the cat.

They

found, in cats with tegmental lesions, fewer spontaneously
firing cells which could be inhibited by dopamine.

Fur-

thermore, in lesioned cats, the dopamine ejection current
required to inhibit striatal cells was significantly greater than in non-lesioned cats.

The subsensitivity to dopa-

mine was specific since after the tegmental lesion there
were no significant changes in the striatal cells' responses to either GABA or L-glutamate.

In contradiction to

the findings of Spehlmann and Stahl (1974) , Yarbrough and
Phillis (1975) reported a supersensitive response of dopaminoceptive cells following unilateral lesions of the substantia nigra in rats.

The supersensitive response was

demonstrated as an increased proportion of cells which were
inhibited by dopamine following the lesion.

In addition,

Yarbrough and Phillis (1975) reported that following the
substantia nigra lesion there was a significant decrease in
the threshold current required for dopamine to inhibit the
firing of glutamate stimulated caudatal cells.

Similar

supersensitivity of dopaminoceptive cells to dopamine has
been reported by Feltz and De Champlain (1972) •

A super-
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sensitive response of dopaminoceptive cells was also observed following chronic haloperidol administration
(Yarbrough, 1975).
In the case of norepinephrine,microiontophoretic
studies have suggested that after 6-0HDA a supersensitivity
develops in cerebellar Purkinje cells (Hoffer et al., 1971)
and hippocampal pyramidal cells (Segal and Bloom, 1974) to
iontophoretically applied NE.

Disconcerting however, were

the findings of a supersensitive response of brain stem
neurons to iontophoretic application of NE after reserpine,
but not after FLA-63 or

~-mpt

(Boakes et al., 1971).

MECHANISMS OF SUPERSENSITIVITY PHENOMENA IN THE CNS

In the central nervous system the mechanism of the
supersensitivity phenomenon has only recently been a subject of investigation.

It was expected that denervation of

dopaminergic pathways could result in an increased activation of dopamine stimulated adenylate cyclase activity by
exogenously administered dopamimetics.

The increased acti-

vation of adenylate cyclase might be a mechanism of supersensitivity.

Dopamine stimulated adenylate cyclase was

postulated to be involved in central dopaminergic neurotransmission (Kebabian and Greengard, 1971).

In fact,the

activation of adenylate cyclase by dopamine was increased
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following radio frequency or 6-0HDA induced lesions of the
substantia nigra of rats (Mishra et al., 1974}.

However,

others could not confirm after intrastriatal 6-0HDA any

'

'

alteration in the DA stimulated activity of mouse striatal
adenylate cyclase (Von Voigtlander et al., 1973}.

Most

recently, an endogenous protein activator which regulates
adenylate cyclase and phosphodiesterase activities was
increased after chronic treatment with either 0(-mpt, reserpine or haloperidol (Gnegy et al., 1976}; this activator
might be involved in the development of dopamine receptor
supersensitivity.

Thus, it remains a problem for further

research to determine the role of DA stimulated adenylate
cyclase in dopamine receptor supersensitivity.
There are several other mechanisms which speculatively may be involved in the development of central dopamine
receptor supersensitivity.

Hormonal mechanisms may alter

receptor responsiveness as was demonstrated for thyroxine
and hypothalamic factors such as thyrotropin releasing
factor (TRF} and melanocyte inhibiting factor (MIF} for
responses to L-DOPA (Engstrom et al., 1974; Plotnikoff
et al., 1971; Huidobro-Toro et al., 1975}.

Since an in-

hibition of protein synthesis blocks the effects of L-DOPA,
it may be speculated that an increase in protein synthesis
may induce a supersensitive response to L-DOPA (Tang et
al., 1974}.

Decreases in either the amount or activity of
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the recently discovered heat stable activator of phosphodiesterase may also induce supersensitivity (Strada et al.,
1974).

Moreover, the finding of prolonged activation of

dopaminergic receptors by cholera toxin (Miller and Kelly,
1975) and the increased sensitivity of mice to apomorphine
and clonidine after repeated electroconvulsive shock
(Modigh, 1975) suggest the possibility of other mechanisms
which control central dopamine receptor sensitivity.

In

addition, other mechanisms, such as an increase in the
amount of neurotransmitter released (Sharpless, 1975) or
the taking over of function by another neurotransmitter
system (Longo, 1975) were also suggested but not yet explored.
In the central nervous system, the mechanism of
changes in receptor sensitivity was most extensively investigated in the pineal gland.

A beta-adrenergic receptor

is thought to regulate the activity of N-acetyltransferase
(NAT) in the pineal gland (Brownstein et al., 1973).

In-

formation about environmental lighting is conveyed to the
pineal via postganglionic sympathetic fibers which have
their cell bodies located in the superior cervical ganglion
(Kappers, 1960).

Denervation via a bilateral superior cer-

vical ganglionectomy resulted in a superinduction of NAT
activity by isoproterenol (Deguchi and Axelrod, 1972).

The

supersensitivity was characterized as the postsynaptic type
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which occurred as soon as 24 hours following denervation
(oeguchi and Axelrod, 1972) •

Denervation of the pineal

did not result in a supersensitive response to dibutyryl
cyclic AMP.

Thus, the mechanism of supersensitivity ap-

peared to be located before the cAMP,"second messenger"
step (Deguchi and Axelrod, 1973) •

Furthermore, a catecho-

lamine induced increase in cAMP could not account for the
supersensitivity since a supersensitive response of adenyl
cyclase to catecholamines did not occur until four weeks
after denervation (Deguchi and Axelrod, 1973) •

Thus, one

may speculate that some other as yet undefined aspect of
the NE-receptor interaction in the pineal could account for
the supersensitivity observed after denervation.

Possible,

some involvement of both RNA and protein synthesis may be
involved as in the case of the changes in the diurnal responsiveness of NAT to induction by catecholamines (Romero
and Axelrod, 1975) •
In other experiments the mechanism of supersensitivity to NE appeared to be more clearly related to an enhanced response of adenyl cyclase to norepinephrine and the
subsequent elevation of cyclic AMP levels.

For example,

two independent groups have documented an enhanced accumulation of cyclic 3'-5' AMP in rat cerebral cortical slices
following intraventricular 6-0HDA treatment (Kalisker et
al., 1973; Huang et al., 1973).

In fact, both an early
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developing prejunctional as well as a later developing
postjunctional type of supersensitivity were suggested in

this preparation.

Thus, the development of supersensi-

tivity of rat cerebral cortical slices to NE partly resembles that observed in sympathetically innervated peripheral tissues after a postganglionectomy (Trandelenburg,
1966).
In contrast to the catecholaminergic neurotransmitter system, our understanding of the mechanism of supersensitivity of central cholinoceptive

receptor~

is minimal.

At least in one case the central supersensitivity to cholinonimetics was shown to arise from a presynaptic loss of
acetylcholinesterase (Bird and Aghajanian, 1975).

Further-

more, we have practically no knowledge concerning the
mechanisms of supersensitivity in central serotonin receptors.

THE APPROACH TAKEN TO ASSESS THE SELECTIVITY OF THE NEUROTOXICITY OF 6-0HDA AND 5,6-0HT

It can be expected on the basis of the preceeding dis-

cussion that a selective neurotoxin may induce, at a particular dose, the depletion of a single neurotransmitter.

There-

fore, to neurochemically assess the selectivity of 6-0HDA
and 5,6-0HT the brain content of four neurotraasmitters
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was measured.

The brain contents of norepinephrine, dopa-

mine, serotonin and acetylcholine were measured after each
neurotoxin treatment in order to:

a) verify the destruc-

tion of a particular neurotransmitter system as evidenced
by a decline in the levels of DA and/or NE in the case of
6-0HDA or 5-HT in the case of 5,6-0HT; b) to assess the
selectivity of destruction by investigating alterations in
the brain content of several other neurotransmitters such
as ACh and 5-HT in the case of 6-0HDA and DA, NE and ACh in
the case of 5,6-0HT.
Since neuronal destruction is considered to result in
changes in postsynaptic receptor sensitivity the use of
postsynaptic agonists acting on the dopaminoceptive, serotonoceptive or cholinoceptive receptor sites would help to
elucidate the selectivity of neuronal destruction induced
by either 6-0HDA or 5,6-0HT.
The postsynaptic state of dopaminergic receptors was
assessed by the use of apomorphine, a postulated direct DA
receptor agonist (Ernst, 1969) •

Since apomorphine is not

taken up by dopaminergic nerve terminals it would not be
useful to demonstrate supersensitivity of the prejunctional
type.

However, apomorphine would be useful in demonstrat-

ing DA receptor supersensitivity of the postsynaptic type.
Thus, any 6-0HDA or 5,6-0HT induced increase in the behavioral response to apomorphine was considered to be evidence

46

for the postsynaptic type of DA receptor supersensitivity.
The behavioral response to L-DOPA was used to test
for the presence of the presynaptic type of DA receptor
supersensitivity as L-DOPA's action depends upon the formation of dopamine (Levitt et al., 1965) which may be taken
up by dopaminergic nerve terminals.

Thus,supersensitivity

to L-DOPA but not to apomorphine would be indicative of
a presynaptic type of DA receptor supersensitivity.
Furthermore, as neuronal destruction may result in
the development of subsensitivity, this was also evaluated
in the case of the dopaminergic neurons with the use of
methamphetamine.

Since methamphetamine's action depends

upon a presynaptic store of catecholamines (Moore et al.,
1970}, any decrease in the action of methamphetamine after
neurotoxin treatment would be indicative of a presynaptic
type of subsensitivity of dopamine receptors.
To test for supersensitivity of serotonergic receptors

the administration of L-5-HTP, which induced head

twitches and tremors in mice (Corne, 1963) was utilized.
It has been considered that the response to L-5-HTP is a
result of 5-HT formed in the brain stem following its decarboxylation (Corne, 1963}.

Moreover, the pharmacologic

action of L-5-HTP does not depend upon the rate limiting
tryptophan hydroxylase step of 5-HT synthesis (GrahameSmith, 1971).

Thus, L-5-HTP could activate the postsynap-
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tic 5-HT receptors in the absence of serotonergic nerve
terminals.

However, any observed supersensitive response to

L-5-HTP may also be of the presynaptic type; as in the absence of nerve terminals there would be impaired reuptake of
the 5-HT formed from 5-HTP.

In contrast, L-tryptophan would

be a poor choice as an agonist to test for 5-HT receptor
supersensitivity since i t depends upon the presence of brain
tryptophan hydroxylase which is located in the serotonergic
neurons, and which may be depleted by neurotoxin treatments.
In addition, the status of central muscarinic cholinoceptive receptors was assessed with tremorine, a compound the action of which is believed to result from a
direct interaction with that receptor {Everett and.Blockus,
1956; Cox and Potkonjak, 1969b). Thus, any increase in the
tremorigenic response to tremorine may reflect a supersensitivity of central muscarinic cholinoceptive receptors.
Behavioral analysis consisted of an examination of
locomotor activity following administration of the neurotoxins since the catecholaminergic system appears to have
a facilitatory role in this behavior.

Destruction of the

catecholaminergic system should be reflected as a depres-

sion of motor activity.

Thus, changes in spontaneous loco-

motor activity may be a supportive argument but may not be
the only argument {cf. above) indicative of a selective
neurotoxin action on the catecholaminergic system.
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Indeed, if either 6-0HDA or 5,6-0HT changed the brain content of more than one neurotransmitter, or changed the sensitivity of more than one postsynaptic receptor, then 6-0HDA
or 5,6-0HT may be classified as non-specific neurotoxins and
possibly as non-selective neurotoxins.

All results must al-

so be interpreted to account for possible direct interactions or interrelationships between several neurotransmitter
systems.

Such interactions may mimic a non-specific action

and must be excluded as the causal factors of multineurotransmitter changes that can be observed following neurotoxin treatment.
Regeneration of axons and axon terminals was reported
following 6-0HDA or 5,6-0HT treatments (cf. below).

In the

case of 6-0HDA, De Champlain (1971) reported a regrowth of
adrenergic fibers in the rat after systemic administration
of 6-0HDA.

The regeneration of monaminergic neurons after

6-0HDA was also observed in the central nervous system
(Nygren et al., 1971).

Similarly, regeneration and sprout-

ing was observed following 5,6-0HT treatment (Bjorklund
et al., 1973; Nobin et al., 1973).

In the case of 5,6-0HT

treatment it was suggested that a functional serotonergic
reinervation takes place (Fuxe et al., 1973) long after the
5,6-0HT treatment.

Because of the regeneration phenomena,

the aforementioned pharmacological, neurochemical and
behavioral tests were investigated at various times
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after the administration of either 6-0HDA or 5,6-0HT in
order to determine the permanence of any observed alterations in receptor sensitivity.
The following pages report the findings of this
study as they relate to the selectivity of action of the
neurotoxins 6-0HDA and 5,6-0HT after intracerebral administration to mice.

The neurochemical, behavioral and pharma-

cological approaches eluded to above were employed in this
study to assess the selectivity of the aforementioned neurotoxins.

METHODS

ANIMALS: AND INTRACEREBRAL 'IN'JECTION TECHNIQUE

Male mice of the ICR strain (Indiana Farms) ranging
in weight from 20 to 25 grams were used.

Seven mice were

housed per cage with food and water ad lib.

The mice were

maintained on a light-dark cycle of 14 hours of light
(0600-2000 hrs.) and 10 hours of darkness (2000-0600 hrs.)
throughout the study.
Either 5,6-dihydroxytryptamine (5,6-0HT), 6-hydroxydopamine (6-0HDA) or the vehicle were injected intracerebrally as described by Haley and Me Cormick (1957).

The

drugs were always injected in a volume of ten microliters
using 2.5 rnm long 27 gauge stainless steel needle attached
to a 50 f{ 1 Hamil ton microsyringe; the tip of the needle
was ground to a slight (0.25 rnm} bevel.

5,6-0HT and 6-0HDA

were freshly prepared prior to injection in a 1:1000 aqueous ascorbic acid solution.

5,6-0HT or 6-0HDA were admin-

istered at the doses of 43 and 70
tively.

~gm

of the base, respec-

These doses were found to produce gross behavioral

changes in pilot experiments.

They were also reported to

be without extensive lethality and were used successfully
in rats.
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India ink, 10 microliters, was used to determine the
distribution of the drug solution following the intracerebral injection (Haley and Me Cormick, 1957).

India ink was

found throughout the ventricular system and the surface of
the cortical areas.

It was assumed that the drug injec-

tions had a similar distribution pattern.

It was further

assumed that the. uptake mechanism of the catecholamine containing nerve terminals and the distribution of the injected drugs were the critical factors with regard to their
destruction.
The site of the intracerebral injection was estimated
in mice sacrificed for neurochemical evaluation.
of injection was found to be 1.7
to the sagittal suture and 0.35

~
~

The site

0.06 rnrn {S. E.) lateral

0.08 mrn (S. E.) posterior

to an imaginary perpendicular to the sagittal suture; the
perpendicular intersected the sagittal suture at the point
where the left and right coronal sutures intersected the
sagittal suture (100 animals).

On average, the tip of the

injection cannula was located in the right lateral ventricle.

When the ventricle was missed the other structures

receiving the injection were primarily the lateral septum
and the putamen.
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l?lfA:RMACOLOGICAL AND. BEHAVIORAL TESTS

LOCOMOTOR ACTIVITY

Leigh Valley photoactometers were used to quantify
the locomotor activity of mice.

Groups of six mice were

placed in photoactometers and their activity was recorded
every fifteen minutes for three hours.
In order to evaluate the effect of 6-0HDA and 5,60HT on locomotor activity following their intracerebral injection, two types of experiments were performed.

One

measurement of activity following the treatment with either
6-0HDA, 5,6-0HT or vehicle involved the repeated assessment
of locomotion on alternate days for a total of 20 days
after intracerebral injection.

Another approach, designed

to negate the conditioning effect of repeated measures of
motor activity, involved the single assessment of motor
activity in different groups of naive animals 1, 4, 10 and
20 days after intracerebral injection.

LOCOMOTOR RESPONSES TO METHAMPHETAMINE. AND" L·- DOPA

The locomotor response to methamphetamine, 2.5 mg/kg,
i.p., was recorded in a similar fashion (cf. above) utilizing repeated measures of locomotor activity in the same
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group as well as single measures in different groups of
mice.

The locomotor activity was recorded every 15 minutes

for 90 minutes prior to and 90 minutes subsequent to the
administration of methamphetamine.
The locomotor response of 5,6-0HT, 6-0HDA and vehicle
treated mice to L-DOPA (100 mg/kg, i.p.) were recorded in a
similar fashion; a 90 minute pre L-DOPA measurement was
combined with a 90 minute post L-DOPA measurement.

The

tests were carried out on the same groups of animals 1, 4,
10, and 20 days after intracerebral injection.

EVERETT TEST

While a monoamine oxidase inhibitor, pargyline, was
utilized by Everett; it was not utilized in this present
investigation.

Evaluation of the behavior response of 5,6-

0HT, 6-0HDA and vehicle treated mice to L-DOPA, 100 mg/kg,
i.p., was carried out by means of the test introduced by
Everett (1962, 1967).
ployed.

Everett's scoring system was em-

Mice were placed in groups of four per cage after

L-DOPA administration, 100 mg/kg, i.p., and observed every
ten minutes for one hour.
assigned to each animal.

The score of 1+, 2+ and 3+ were
The evaluation was based on the

presence of piloerection, exophthalmos, salivation, Straub
tail grades, reactivity to external stimulation (character-
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ized by jumping, squeaking and kicking), and of aggressive
and stereotypic behaviors.

For each group of mice the per-

centage of animals exhibiting a maximal score of 1+, 2+ and
3+ was calculated.
All mice were scored after 100 mg/kg, i.p. of L-DOPA.
The 1+ response. consisted of none or slight salivation, a
slight or no increase in locomotor activity, and Straub
tail grade +1 or +2.

The mouse was classified as having

Straub tail grade +1 when it held its tail parallel to the
horizontal surface with the tip pointing caudally.

The

mouse was classified as having Straub tail grade +2 when
it held its tail erect and perpendicular to the horizontal
surface.

The vehicle treated mice typically would show

the 1+ response.
The 2+ response to L-DOPA consisted of distinct
salivation, a definite increase in motor activity, Straub
tail grade +3, and increased reactivity to external stimuli
characterized by darting or aggressive posturing.

The

mouse was classified as having Straub tail grade +3 when it
held its tail arched over its back and with the tip pointing rostrally.

The 2+ response to DOPA was observed only

occasionally in vehicle treated mice, primarily at the
early time after intracerebral injection, eg. 4 hours.
The 3+ response to L-DOPA, 100 mg/kg, i.p., consisted
of marked salivation, a marked increase in locomotion
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characterized by episodic or continuous running or darting,
Straub tail grade +3, spontaneous jumping, stereotypic behavior, aggressive posturing and marked hyperirritability
expressed by squeaking, jumping, kicking, darting, running
and aggressive attack in response to external stimuli.

The

external stimuli consisted of lifting the cage top and
lightly touching the side of each mouse with the side of a
glass stirring rod.

Mice which did not exhibit hyperirri-

tability would tolerate the external stimuli, as following
the stimulus, the mouse would walk away and resettle in a
different corner of the cage.

Vehicle treated mice never

exhibited 3+ L-DOPA response.

BEHAVIORAL RESPONSE TO APOMORPHINE

The response of 5,6-0HT, 6-0HDA and vehicle treated
mice to apomorphine, 40 mg/kg, i.p., was evaluated by observing spontaneous jumping, stereotypic climbing behavior,
rigid gait, mouthing of sawdust and licking of the cage; in
addition, some mice reacted to external stimuli by jumping,
kicking and running.

In an all or none fashion, the per-

centage of mice exhibiting hyperreactivity (the running,
kicking and jumping response to external stimuli) and/or
spontaneous jumping behavior were recorded and classified
as having a supersensitive response to apomorphine.

In
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contrast to the supersensitive response of neurotoxin
pretreated mice,the vehicle treated animals exhibited only
stereotypic climbing behavior, licking of the cage and
mouthing of sawdust along with slightly increased motor
activity.

Observation continued for one hour after apo-

morphine; after this time the mice appeared normal.

QUANTIFICATION OF TREMORS

Tremors elicited by tremorine (10 mg/kg, i.p.) or
L-5-HTP (200 mg/kg) were quantified 4 days, 10 days and
20 days following intracerebral injection of 6-0HDA, 5,60HT or ascorbic acid vehicle.

A single mouse was placed

in a small plastic cage, suspended from a Grass FT-10
force transducer.

The tremors were recorded on one chan-

nel of a Beckman Dynograph and integrated on another channel.

The average number of integrator resets per minute

during four respective five minute periods was calculated
for each animal 5, 15,30 and 60 minutes following the administration of either tremorine or L-5-HTP.

The neuro-

toxin induced changes in the tremorigenic effect of tremorine were estimated by comparing the mean integrated
tremor responses for each of the three groups.
Besides inducing tremor, L-5-HTP administration (200
mg/kg, i.p.) elicited additional symptoms which included
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head-shaking, abnormal gait and body position (spread eagle
posture) and retrograde movements; marked flushing of ears
and paws could be readily observed; finally, when 5-HTP
was given to 5,6-0HT pretreated mice, death occasionally
resulted.

The fraction of animals in which the presence or

absence of these symptoms could be observed was evaluated
in 5,6-0HT and vehicle pretreated animals following 5-HTP
challenge both in the presence or absence of a decarboxylase inhibitor, RO 4-4602/1.

NEUROCHEMICAL METHODS

For the measurement of the bioamines the mice were
sacrificed by decapitation, always between 7:00 and 11:00
A.M. to minimize diurnal influences.

Brain levels of dopa-

mine (DA) , norepinephrine (NE) , serotonin (5-HT) and
acetylcholine (ACh) were measured in the portion of the
brain composed of the cerebral hemispheres, basal ganglia,
thalamus, hypothalamus, corpora quadrigemina and midbrain;
the olfactory bulbs, cerebellum, pons and medulla were discarded (Figure 1).

The sample was rinsed, blotted, weighed

and placed in a liquid nitrogen within one minute of
decapitation.
A modification of the ion exchange-column chromatographic method of Atack and Magnusson (1970) was used for

I

I

FIGURE 1.

A sagittal view of the mouse brain.

The dashed lines indicate

the planes in which cuts were made to isolate the brain part used for
neurochemical analysis.

The portion of tissue between the dashed lines

was used for the analysis.
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the separation of NE, DA and 5-HT.

Essentially, the spec-

trophotoflurometic methods of Bertler et al.

(1958a, b),

Carlsson and Waldeck (1958) and Maickel et al.

(1967) were

employed for the determination of NE, DA and 5-HT, respectively as described in detail below.

Four brains were

pooled for each determination of NE, DA and 5-HT.
After extraction with formic acid and electrophoretic
separation, ACh was determined by the choline kinase method
of Reid et al.

(1971) as described in detail below.

ACh

determinations were carried out on single brains.

EXTRACTION OF THE CATECHOLAMINES AND SEROTONIN

The tissue was homogenized in 7.8 ml of 0.4 N perchloric acid (PCA) and 0.2 ml of 2% ascorbic acid; an additional 3 ml of 0.4 perchloric acid (PCA) was used to
rinse the homogenizing pestle into the centrifuge tube.
The homogenate was kept on ice and centrifuged at 3,000 RPM
for 15 minutes.

The supernatant was decanted and filtered

through Whatman glass fiber filter paper.

The filtrate

volume was recorded and each sample was adjusted to pH 6.5.
The neutralized extract was placed in -4 ~ cold for 10
minutes.

Following cooling the samples were centrifuged

for 10 minutes at 3,000 RPM.

The resultant supernatant was

decanted onto the previously prepared columns utilizing the
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procedure of Bertler et al.

(1958).

pREPARATION OF RESIN FOR THE ELUTION OF CATECHOLAMINES AND
SEROTONIN

The BioRad AG50W -4X, 200-400 mesh H+ form (Strong
cation Exchange) resin was batch processed in the following
way prior to the preparation of the columns.

100 Gms. of

resin was stirred with 100 ml of 2 N NaOH for 20 minutes.
Triple distilled water was used in 100 ml quantities to
wash away the NaOH until the final pH was less than 9.5.
Subsequently, 100 ml of 2 N HCl was stirred with the resin
for 20 minutes.

This was followed by triple distilled

water washes until the pH was greater than 5.

The final

washing was with 100 ml of redistilled ethanol; the mixture was stirred for 20 minutes, followed by triple distilled water washes until the odor of ethanol was no longer
apparent.

The resin was packed into columns with triple

distilled water.

A volume of 20 ml of 0.1 M phosphate

buffer at pH 6.5 containing 0.1% EDTA was passed through
each column prior to use.
below was followed.

The elution procedure described
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ELUTION OF THE CATECHOLAMINES AND SEROTONIN

The amines were eluted according to the method of
Atack and Magnusson (1970) •
The sample was passed through the BioRad AGSOW resin
(4X, 200-400 mesh) at 1 drop per 10 seconds followed by
40 ml of triple glass distilled water at 1 drop every 5
seconds.

Eleven ml of 1 N HCl was added and allowed to

flow at 1 drop per 10 seconds.

The first 3 ml of this HCl

eluate were discarded and the subsequent 8 ml were collected and contained NE.
Following the elution of NE 13 ml of 1 N (50% ethanelie} HCl was allowed to pass through the column at a flow
rate of 1 drop per 7 seconds.

The first ml of the ethane-

lie HCl eluate was discarded.

The next 5 ml were collected

and contained DA; the next 7 ml were also collected and
contained 5-HT.
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ASSAY OF NOREPINEPHRINE

The trihydroxyindole technique of Bertler et al.
(1958) was used.

The following protocol was used.

STANDARD

REAGENT
BLANK

TISSUE
SAMPLE

INTERNAL
STANDARD

TISSUE
BLANK

distilled H o
2

3.80

3.90

2.90

2.80

2.90

0.1 M PO
buffer pa 6.5

0.50

0.50

0.50

0.50

0.50

1.00

1.00

1.00

sample eluate
at pH 6.5
NE standard
(Lc.c.gm/ml)

0.10

0.5% ZnS0

0.05

0.05

0.05

0.05

0.05

0.05

0.05

0.05

0.05

0.05

0.50

0.50

4

0.25%
K3 Fe(CN) 6

0.10

5 MINUTE WAIT
2% ascorbic
acid, 5N NaOH

0.50

0.50

5N NaOH

0.45
10 MINUTE' WAIT

2% ascorbic
acid

0.05
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samples were placed in an Aminco Bowman spectrophotofluorometer and read with wave lengths for excitation of
400

m~

and for emission of 50 5 mx. •

ASSAY OF DOPAMINE

A modification of the dihydroxyindole technique of
Carlsson and Waldeck (1958) as modified by Glisson et al.
(1972) was used.

The following protocol was used for the

development of the fluorophore.
STANDARD

REAGENT
BLANK

TISSUE
SAMPLE

INTERNAL
STANDARD

TISSUE
BLANK

50% Ethanolic
HCl lN pH 5.4

2.00

2.00

distilled H2 o.

1.05

1.30

1.30

1.05

1.30

citrate P04
buffer pH 5.4

0.50

0.50

0.50

0.50

0.50

DA standard
(1 )(gm/ml)

0.25

0.25

sample (unneutralized)

1.65

sample-pH 5.4

2.00

2.00

NaS0 3 -NaOH
0.02 N Iodine

5N Acetic Acid

0.50
0.10

0.10
0.10
5 MINUTE WAIT
0.50
0.50
0.50
5 MINUTE WAIT
1.60
1.60
1.60

0.10

0.10

0.50
1.60

1.60
0.35

64

samples were heated at 100° C for fifteen minutes, cooled
and the fluorescence read in an Aminco Bowman spectrophotofluorometer.
m~

The fluorescence wave lengths used were 330

for excitation and 380

m~

for emission.

ASSAY OF SEROTONIN

The o-phthalaldehyde {OPT) technique of Maickel et
al. {1968} was used.

Briefly, 0.5 ml of the 5-HT eluate

was mixed with 1 ml of 4 mg% OPT in 10 N HCl.

The resul-

tant mixture was heated at 100°C for ten minutes, cooled to
room temperature and read in the Aminco Bowman spectrophotofuorometer with the wave lengths of excitation at
360 mM. and emission at 4 70 m)A. •

The slit arrangement used

was: excitation slit 2, cuvette slit 5, emission cuvette
slit 2, emission slit 5, phototube slit 1.

EXTRACTION AND ASSAY OF ACETYLCHOLINE

The technique of Haubrich and Reid {1973} was
utilized.

The ACh and choline were extracted from brain

tissue with a 15% solution of lN formic acid in acetone
(5 ml per gram of tissue) •

A second extraction was carried

out with a 10% solution of lN formic acid in acetone {1 ml
per gram of tissue) .

The two extract supernants were com-

65

bined with an equal volume of water saturated ether and
shaken to extract the acetone into the ether.
layer was then aspirated and discarded.

The organic

The solvents re-

maining in the aqueous phase were blown off with a stream
of air.

After the extract was centrifuged to remove par-

ticulate matter the resulting supernatant was lyophylized.
The lyophylized extract was then dissolved in 20 ml
of distilled water.

15 ml of the clear redissolved extract

was spotted in three equal aliquots on Whatman 3 MM chromatographic paper allowing for drying between each spotting.
The paper was also spotted with marker spots of choline
and acetylcholine as well as internal standards.

The paper

was placed in a flat plate electrophoresis unit with the
origin toward the positive electrode.

The paper then was

moistened with a brush so that the electrophoresis pyridine - formic acid buffer approached each side of the
origin simultaneously.

The electrophoresis unit was set to

run at 800 volts for 2-3 hours.
Following electrophoresis the paper was air dried.
The marker spots were identified by exposure to iodine
vapor.

After marking the location of these spots with a

pencil the iodine was removed from the paper by exposure to
steam.

A 20x25 mm template was used to mark off the sample

spots.

The paper was cut and rolled into a tight cylinder

with forceps. One ml of distilled water was added to a
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culture tube containing the paper to elute the choline and
acetylcholine by agitating with a vortex mixer for one
minute and allowing it to stand for fifteen minutes.
Acetylcholine was hydrolysed as a 0.5 ml aliquot
of the electrophoresis paper eluate was mixed with 10
of concentrated ammonium hydroxide.

~1

The resultant mixture

was heated for twenty minutes on a boiling water bath.

The

samples were then dried in a vacuum at 50-60°C.
Following drying, 0.1 ml of a choline kinase and ATP
solution containing ATP-

A- 32

P (yielding approximately

1x10 5 - 3xlo 5 CPM per 0.1 ml) was added to the sample
tubes.

The tubes were agitated to dissolve the choline.

The samples were then incubated at 37°C for 2 to 4 hours.
Ten

~1

containing 100

~g

of phosphorylcholine chloride

was added to each sample as a carrier.

1.5 ml of pH 10-

Tris-Mgso4 buffer was also added to each sample.

The con-

tents of the sample tubes were added to a column containing
Dowex I anion exchange resin (chloride form, 8% cross linked, dry mesh 200-400).

An additional 4.5 ml of pH 10-Tris-

Mgso4 buffer was also added to the column as a wash.

The

total effluent and eluate were collected and counted in a
liquid scintillation counter.

The brain content of ACh was

calculated using the internal and external standards processed in parallel with the samples.
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DRUGS

L-DOPA was dissolved with warming in sufficient 0.1 N
HCl and distilled water to produce a 10 mg/ml solution at
pH 3.5; RO 4-4602/1 and L-5-HTP were dissolved in water
with warming.

Tremorine HCl and methamphetamine HCl were

dissolved in 0.9% saline.

Apomorphine HCl was dissolved

in 1:1,000 aqueous ascorbic acid.
tered intraperitoneally.

All drugs were adminis-

Methamphetamine HCl, L-DOPA, L-5-

HTP and DL-alpha-methyl tyrosine methyl ester HCl were
purchased from the Sigma Chemical Company.

RO 4-4602/1

and tremorine were graciously supplied by Roche, Inc.,
Nutley, New Jersey and Abbott Labs, Abbott Park, Illinois
respectively.
Inc.

Apomorphine HCl was purchased from Merck,

Commercially available USP grade ascorbic acid was

employed.

Both 6-hydroxydopamine HBr and 5,6-dihydroxy-

tryptamine creatinine sulfate dihydrate were purchased from
the Regis Chemical Company, Morton Grove, Illinois.
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STATISTICS

Dr. T. Hoffman of the biostatistical department of
Lederle Laboratory in Pearl River, New York served as the
statistical consultant.
dures were utilized.

The following statistical proce-

The "SAS" statistical analysis system

developed by Anthony James Barr and James Howard Goodnight
of the Department of Statistics, North Carolina State University, Raleigh, North Carolina was utilized on an IBM 360
computer.

The neurochemical data were analysed by analysis

of variance and multiple comparisons were made by means of
the Newman-Keuls multiple range test.

Repeated measures of

motor activity were analysed by a least squares regression
and analysis of variance.

The locomotor activity data de-

rived from the single test procedure were also analysed by
analysis of variance and the mean activity of the groups
were compared with the Newman-Keuls multiple range test.
Significance of the occurrence of supersensitivity was
assessed in both the Everett test and the apomorphine challenge test by means of the Chi-square statistic.

The quan-

titative integrated readings of tremorigenic activity following either oxotremorine or L-5-HTP were analysed by
means of the Mann Whitney U-test as well as the KruskalWallis test.

RESULTS

NEUROCHEMICAL FINDINGS

The values for the various arnines were determined

in the contiguous brain part which included the cerebral
hemispheres, basal ganglia, thalamus, hypothalamus, corpora
quadrigemina and midbrain, hereafter referred to as
"brain"; the brain parts which were not analyzed were the
olfactory bulbs, cerebellum and pons-medulla (Figure 1}.

SEROTONIN

Mouse brain levels of serotonin were altered by the
intracerebral administration of either 6-0HDA or 5,6-0HT.
The brain levels of 5-HT in vehicle treated mice were not
found to differ significantly on any of the days tested.
When compared to the vehicle treated animals, both 6-0HDA
and 5,6-0HT significantly decreased the brain levels of
serotonin; these decreased serotonin levels were observed
on each of the days tested.

Four, 10 and 20 days after

the intracerebral injection of 70

~gm

of 6-0HDA, mouse

brain levels of 5-HT were decreased by 22%
{p£.0.01) and 38% (p (.0.01), respectively.
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(p~0.05},

39%

On the 4th,

TABLE 1
BRAIN LEVELS (IN MICROGM/GM) OF DA, NE AND 5-HT FOLLOWING
VEHICLE, 6-0HDA OR 5,6-0HT TREATMENT
5-HT
4

Da~s

+ 0.03 (19)

10 Da;LS
0.59

-+

20

Da~s

+ 0.02 {16)

A$C

0.49

6-0HDA

0.38 + 0.03 (7)

0.36 + 0.05 (8)

0.34 + 0.01 (8)

5,6-0HT

0.23 + 0.06 (12)

0.29 + 0.02 (8)

0.33 + 0.04 (8)

0.03 (16)

0.55

DA

-...)

0

ASC

1.22 + 0.18 (25)

1.24 + 0.09 (15)

1.04 + 0.08 (15)

6-0HDA

0.46 + 0.10 (11)

0.37 + 0.06 (8)

0.59 + 0.06 (6)

5,6-0HT

0.55 + 0.10 (16)

1.24 + 0.14 (7)

0.89 + 0.05 (8}

-

NE
ASC

0.56 + 0.01 (23)

0.54 + 0.01 (16)

0.52 + 0.05 (20}

6-0HDA

0.05 + 0.01 (8)

0.20 + 0.01 (8}

0.14 + 0.01 (13)

5,6-0HT

0.17 + 0.03 (15)

0.46 + 0.03 (8)

0.62 + 0.12 (8}

-
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LEGEND FOR TABLE 1.
Mouse brain levels of 5-HT, DA, and NE in

~gm/gm

wet weight on various days after an intracerebral injection
with either 6-0HDA, 5,6-0HT or ascorbic acid vehicle.
brains were pooled for each determination.

Four

The number of

determinations are indicated within the parenthesis.

Sig-

nificance of differences were determined by the NewmanKeuls multiple range test.
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10th and 20th days after the intracerebral injection of
43 Agm of 5,6-0HT, the mouse brain levels of 5-HT were
found to be decreased by 53% (p
40% (p<.O.Ol), respectively.

< 0. 01) ,

51% (p ( 0. 01) and

There were no significant

differences in the degree of serotonin depletion on the
4th, lOth or 20th days after 6-0HDA.

Furthermore, there

were no significant differences in the degree of serotonin
depletion on the 4th, lOth and 20th days after 5,6-0HT
(Table 1).

Thus, both 6-0HDA and 5,6-0HT treatments re-

sulted in prolonged decreases in mouse brain serotonin
content.

DOPAMINE

Mouse brain levels of DA were differentially altered
by the intracerebral injection of either 6-0HDA or 5,6-0HT.
The levels of DA in vehicle treated mice were not found to
differ significantly from each other on any of the days
tested.

Four, 10 and 20 days after the intracerebral in-

jection of

70~gm

of 6-0HDA, the mouse brain levels of DA

were 62%, 70% and 43% below the levels observed in the
vehicle treated mice, respectively.

These reductions in

brain DA levels by 6-0HDA were at the p
statistical significance.

< 0. 01

level of

Furthermore, the decreased brain

DA levels which were observed in the 6-0HDA treated animals
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on the 4th, lOth and 20th post-treatment days did not differ significantly from each other.

Thus, the intracerebral

injection of 6-0HDA induced a prolonged and sustained depletion of DA in the mouse brain.
The depletion of brain DA by the 5,6-0HT treatment
was not as long lasting as that induced by the 6-0HDA
treatment (Table 1) •

Only on the 4th day after the intra-

cerebral injection of 43

~gm

of 5,6-0HT, was the mouse

brain level of DA significantly below that of the vehicle
treated mice (p <. 0. 01) •

Furthermore, on the. lOth and 20th

days after 5,6-0HT treatment, the level of DA was significantly greater than that observed on the 4th day after
5,6-0HT treatment (p

< 0.05).

NOREPINEPHRINE

The level of NE in vehicle treated mice was not found
to differ significantly on any of the days tested.

Mouse

brain levels of NE were differentially altered after the
intracerebral injection of either 6-0HDA or 5,6-0HT.

In

those mice which had received the 6-0HDA treatment, the
levels of NE in brain were significantly below those of
mice which had received isovolumetric, intracerebral injections of the ascorbic acid vehicle.

The 6-0HDA treat-

ment resulted in reductions of the NE content in brain by
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91%, 63% and 73% respectively, on the 4th, lOth and 20th
days after the injection ( all the values were significantly below the control values at the l.evel of p <0. 01) •
6-0HDA depleted the brain level of NE to a greater extent
on the 4th as compared to the lOth post-treatment day
(p ( 0 • 0 5) •

Thus, 6-0HDA when administered intracerebrally

to mice induces a prolonged depletion of brain NE content.
Similar to the 5,6-0HT effect on the brain DA levels
and as compared to the effect of 6-0HDA, the depletion of
brain NE by the 5,6-0HT treatment was not as long lasting
as that induced by the 6-0HDA treatment (Table 1) •

The

mouse brain level of NE was significantly below that of
vehicle treated mice only on the 4th day after the intracerebral injection of 5,6-0HT.

Furthermore, the levels of

NE in the 5,6-0HT treated mice were significantly greater
on the lOth and 20th days after treatment than those observed in mice which were tested 4 days after 5,6-0HT
treatment.

In addition, the levels of NE in the 5,6-0HT

treated mice were also significantly greater than those
observed in the 6-0HDA treated mice on both the lOth and
20th post-treatment days.

Therefore, 5,6-0HT treatment de-

pleted the brain content of NE in a transient manner with
the levels returning to normal by the lOth day after treatment.

This transient effect of 5,6-0HT treatment on brain

NE content is in direct contrast to the prolonged (up to
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20 days) depletion of brain NE which was induced by the
6-0HDA treatment.

ACETYCHOLINE

The intracerebral injection of 70 Aq.m of 6-0HDA or
43 ){gin of 5, 6-0HT did not alter the mouse brain levels of
ACh as compared to the vehicle treated mice (Table 2) •

The

ACh data obtained following 6-0HDA treatment with the electrophoretic technique of Reid et al. (1971), confirm those
previously reported by Barnes et al. (1973a, b) obtained
with a bioassay method of ACh analysis.

AMINES AFTER L-DOPA

The i.p. administration of L-DOPA (100 mg/kg) lowered
the brain 5-HT levels (p

< 0. 0 5) of mice which had received,

4 days earlier, an intracerebral injection of either ascorbic acid vehicle or 5,6-0HT (Table 3).

L-DOPA did not

appear to affect the brain levels of 5-HT in mice which had
been pretreated with 6-0HDA.

The 5-HT depleting action of

L-DOPA has been previously reported (Bartholini, Da Prada
and Pletscher, 1968; Butcher and Engel, 1969; Everett and
Borcherding, 1970).
The mouse brain levels of DA were significantly

TABLE 2
BRAIN LEVELS (IN NANOM/GM) OF ACH FOLLOWING
6-0HDA AND 5,6-0HT TREATMENT

4 DAYS

4 DAYS + L-DOPA

4 DAYS + 5-HTP

20 DAYS

ASC

14.5 + 0.6 (22)

15.3 + 1.3 (16)

22.2 + 2.1 (17)

15.6 + 1.1 (19)

6-0HDA

13.0 + 0.9

(11)

14.5 + 1.2 (12)

21.6 + 0.9 (11)

16.5 + 2.1 (12)

5,6-0HT

16.4 + 1.4 (19)

15.6 + 1.3 (16)

16.3 + 2.5 (15)

15.8 + 0.9 (8)
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LEGEND FOR TABLE 2.
Mouse brain content of ACh in nM/Gm fresh weight
4 and 20 days after the intracerebral injection of either
6-0HDA (70 .A(gm/10 )..(1) , 5, 6-0HT ( 43 .L(gm/10 ..t( 1) or 10 ).(1 of
o.l% ascorbic acid vehicle.
for each determination.

Single mouse brains were used

The number of determinations are

indicated in the parenthesis.

Neither 6-0HDA nor 5,6-

0HT affected the levels of ACh 4 or 20 days after i.e.
injection.

L-DOPA 100 mg/kg, i.p. ,15 minutes prior to

sacrifice did not affect the brain levels of ACh, in
either 6-0HDA, 5,6-0HT or vehicle treated mice.

L-5-HTP

200 mg/kg, i.p. 15 minutes prior to sacrifice increased
the brain levels of ACh in vehicle treated (ASC) and
6-0HDA treated mice but not in 5,6-0HT treated mice
(p<. 0.025).

TABLE 3
BRAIN LEVELS OF 5-HT, DA AND NE FOLLOWING THE ADMINISTRATION OF L-DOPA OR 5-HTP
FOUR DAYS AFTER INTRACEREBRAL INJECTION OF VEHICLE, 6-0HDA OR 5,6-0HT
4 DAYS

4 DAYS + L-DOPA

4 DAYS + L-5-HTP

5-HT
ASC
6-0HDA
5,6-0HT

0.49 + 0.03 (19)
0.38 + 0.03 (7)
0.23 + 0.06 (12)

0.27 + 0.1
(19)
0.41 + 0.13 (8)
0.10 + 0.01 (12)

0.93 + 0.14 (16)
0.76 + 0.19 (8)
0.70 + 0.17 (8)

DA
ASC
6-0HDA
5,6-0HT

1.22 + 0.18 (25)
0.46 + 0.10 (11)
0.55 + 0.10 (16)

1.87 + 0.22 (24)
0.74 + 0.09 (7)
1.60 + 0.24 (16)

1.23 + 0.10 (14)
0.68 + 0.06 (8)
1.31 + 0.08 (8)

NE
ASC
6-0HDA
5,6-0HT

0.56 + 0.01 (23)
0.05 + 0.01 ( 8)
0.17 + 0.03 (15)

0.56 + 0.06 (24)
0.41 + 0.06 (8)
0.26 + 0.03 (16)

0.69 + 0.08 (18)
0.31 + 0.03 (12)
0.37 + 0.04 (7)

-...!
00
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LEGEND FOR TABLE 3.
Mouse brain levels of NE, DA and 5-HT in

~gm/Gm.

wet weight four days after intracerebral injection with
either 6-0HDA, 5,6-0HT or ascorbic acid vehicle.

Brain

bioamine levels are also listed for animals which had
received either L-DOPA, 100 mg/kg, i.p. or L-5-HTP, 200
mg/kg, i.p. fifteen minutes prior to sacrifice.
brains were pooled for each determination.

Four

The number of

determinations are indicated within the parenthesis.
Significance of differences were determined by the NewmanKeuls multiple range test.
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elevated (p

~0.01)

15 minutes after L-DOPA administration

(100 mg/kg, i.p.) in mice which had received an intracerebral injection, 4 days previously, of vehicle or 5,60HT.

Although the increase in brain dopamine after L-DOPA

in 6-0HDA treated mice was not statistically significant in
this study, we have previously reported (Barnes.et al.,
1973b) that L-DOPA can elevate the depleted brain levels
of DA in 6-0HDA treated mice.

The evidence indicates that

L-DOPA treatment can increase the brain levels of DA in
6-0HDA and 5,6-0HT treated mice, but the levels of DA did
not exceed those of vehicle treated mice (Table 3)
et al., 1973b,c).

(Barnes

Thus, the depletion of DA 4 days after

intracerebral injection of 5,6-0HT and of 6-0HDA 2 and 10
days after intracerebral injection can be antagonized and
the DA somewhat elevated by L-DOPA administration.

Without

further studies it can not yet be established whether the
maximal increases in brain DA induced by L-DOPA administration to vehicle treated mice can, in fact, be achieved in mice
pretreated with the neurotoxins 6-0HDA or 5,6-0HT; no other
published study has, as of yet, addressed itself to this
question.
The mouse brain levels of NE were also elevated 15
minutes after L-DOPA administration (100 mg/kg, i.p.) in
mice which had previously received an intracerebral injection, 4 days earlier, of 6-0HDA (p( 0.05).

After L-DOPA
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administration the brain content of NE in· 6-0HDA treated
mice was not significantly different from that of vehicle
treated mice, suc;1gesting a restoration by. L-DOPA of the
brain NE content of 6-0HDA treated mice to normal or near
normal levels.

Although the 5, 6-0HT treated animals also

exhibited an increase in the brain content of NE after
L-DOPA,. that increase was not statistically significant.

In

fact, after L-DOPA the 5,6-0HT treated mice still had a
brain level of NE which was signif.icantly below that of
vehicle treated mice {p£ 0.05)

(Table 3).

Control mice

which were treated with the ascorbic acid vehicle. did not
exhibit NE elevation after L-DOPA administrati.on.

Thus,

the difference in the capacity to restore .the brain content
of NE of the 5,6-0HT and 6-0HDA treated mice in response to
L-DOPA administration may, in part, explain the differences
in behavioral response of these mice to L-DOPA; these results will be described in a subsequent section.
The i.p. administration of L-DOPA (100 mg/kg) did not
affect the brain content of ACh mice which had,. 4 days previously, received intracerebral injections of either 6-0HDA,
5, 6-0HT or vehic.le .(Table 2) •

AMINES AFTE'R 'S-HTP

Fifteen minutes after the injection of L.-5-HTP {200
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mg/kg, i.p.), the brain content of 5-HT was increased in
mice which received, 4 days previously, an intracerebral
injection of either vehicle, 6-0HDA or 5,6-0HT (Table 3).
The L-5-HTP treatment increased the 5-HT content of vehicle
treated mice by 90% (p <. 0. 01), of 6-0HDA treated mice by
100% (p<O.OS) and of 5,6-0HT treated mice by 204% (p<
0.01).

Thus one may conclude that the pretreatment with

either ascorbic acid vehicle, 6-0HDA or 5,6-0HT, in the
dose employed, did not change the ability of L-5-HTP to
increase the brain content of 5-HT.

After L-5-HTP the

levels of 5-HT in 6-0HDA or 5,6-0HT treated mice were not
significantly different; a fact which may account for a
lack of difference between these groups in their behavioral
response to L-5-HTP (cf. below).
L-5-HTP administration did not alter the levels of DA
in mice which, 4 days earlier, received an intracerebral
injection of vehicle or 6-0HDA.

After L-5-HTP administra-

tion, the content of DA in brains of mice which received
6-0HDA was still below that of mice had received vehicle
treatment (p

< 0 .05).

An

unusual result was that after

L-5-HTP, the level of DA was increased in 5,6-0HT treated
mice when compared to 5,6-0HT treated mice which were not
given L-5-HTP.

Everett (1974) had reported that 5-HTP does

not markedly affect the levels of DA in mice which did not
receive either 6-0HDA or 5,6-0HT.
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Fifteen minutes after the administration of L-5-HTP
(200 mg/kg, i.p.) the brain levels of NE were not significantly altered in vehicle or 5,6-0HT treated mice.

Although

the brain NE content increased after L-5-HTP in 6-0HDA
treated mice (p ~ 0. 05) the NE· level was still markedly below that of mice which had received an intracerebral injection of the vehicle and, 4 days later, 5-HTP (p <. 0. 01) (Table
3).

Thus, L-5-HTP administration (200 mg/kg, i.p.) could

not restore the brain content of NE to normal levels in mice
which had been depleted of NE by prior intracerebral treatment with either 6-0HDA or 5,6-0HT.
L-5-HTP (200 mg/kg, i.p.) increased the mouse brain
content of ACh in animals which had received, 4 days previously, an intracerebral injection of vehicle or 6-0HDA
(Table 2).

After L-5-HTP, the content of ACh in mouse brain

was increased by 53% (p '0. 025) in vehicle treated animals
and by 66% (p <. 0. 025) in 6-0HDA treated animals.

L-5-HTP

was without effect on the brain content of ACh in mice which,
4 days previously, had received an intracerebral injection
of 5,6-0HT (Table 2).

These results suggest an interaction

between the serotonergic and the cholinergic systems and
require further study.
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- BEHAVIORAL F'IND'INGS

LOCOMOTOR ACTIVITY - SINGLE TEST PROCEDURE

The locomotor activity of mice was assessed at
various times after 6-0HDA, 5,6-0HT or vehicle treatment.
In the single test procedure naive mice were exposed only
once to the locomotor activity chamber.

The locomotor

activity of mice in the single test procedure was markedly
depressed on the 1st day following the intracerebral injection of either 6-0HDA or 5,6-0HT in doses of 70 or 43
10

~1,

respectively {Figure 2).

~gm/

When compared on the 1st

post-treatment day to the ascorbic acid treated groups, the
6-0HDA and 5,6-0HT treated groups exhibited a depression of
spontaneous locomotor activity which was statistically
significant to the p<. 0.001 level.

The activity of the

6-0HDA treated groups were not significantly different from
that of the vehicle treated animals on the 4th, lOth and
20th post-treatment days.

Thus, the locomotor activity of

6-0HDA treated mice recovered completely by the 4th day
after treatment.

However, the depression of locomotor

activity lasted longer in 5,6-0HT treated animals.

Al-

though some recovery was evident as on day 4, the activity
was significantly greater than on day 1 {p <. 0. 005), the
5,6-0HT treated animals did not show any additional in-
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LEGEND FOR FIGURE 2.
The cumulated locomotor activity of mice, recorded
at fifteen minute intervals for three hours on various
days following intracerebral injection of ascorbic acid
vehicle (Asc), 6-0HDA or 5,6-0HT.

Each point represents

the mean locomotor activity of three groups of six mice;

s.E.M. values are shown for the cumulative activity of
180 minutes.

Different groups of mice were employed on each

day ("single test").

The Newman-Keuls multiple range

test as applied to a two factor ANOV was used to determine
the significance of the differences from control values
at three hours.

On day 1 both 5,6-0HT and 6-0HDA treated

groups were significantly less active than controls
(**;

p < 0. 001) •

Only the 5, 6-0HT treated mice were signif-

icantly less active than controls on days 4 and 10 (*:
p

< 0. OS);

there were no significant differences between

the three groups on day 20.

REGRESSION OF LOCOMOTOR ACTIVITY AFTER VEHICLE, 6-0HDA, OR 5,6-0HT TREATMENT
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LEGEND FOR FIGURE 3.
The locomotor activity of mice was recorded for a
total of 90 minutes on various days after intracerebral
injection of either ascorbic acid vehicle, 70
6-0HDA or 43

~gm

of 5,6-0HT.

~gm

of

The same mice were tested

every other day beginning with the 1st day after intracerebral injection ("repeated" test).

Each point repre-

sents the mean locomotor activity of 3 groups of 6 mice.
A least squares fit of a quadratic (parabolic} curve
represents the regression observed for the Asc and the
5,6-0HT groups (r-square
tively} .

= 0.9222

and 0.7978, respec-

A simple linear regression represents the 6-

0HDA regression (r-square = 0.5013}.

The 6-0HDA treated

groups were significantly below control (p ~ 0. 05) on each
of the 19 days.
than controls (p

The 5,6-0HT groups were significantly less

< 0. 05}

cerebral injection.

up to the 5th day after intra-

The 5,6-0HT and 6-0HDA treated groups

were not significantly different from each other.
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crease in activity between the 4th and lOth day.

The data

indicate that in the case of the 5,6-0HT treated mice, a
full recovery of the spontaneous locomotor activity did not
occur until sometime after the lOth post-treatment day.

LOCOMOTOR ACTIVITY - REPEATED TEST PROCEDURE

The results obtained with the repeated locomotor
activity test (cf. Methods) were similar to those obtained
with the single test procedure.

A marked depression of

spontaneous locomotor activity was observed on the lst day
following the intracerebral injection of either 6-0HDA or
5,6-0HT (Figure 3).

The vehicle treated animals showed the

expected habituation to the locomotor chamber, their locomotor activity decreasing throughout the 19 days of the
experiment.

In contrast, the marked initial reduction in

locomotor activity exhibited by the 5,6-0HT treated mice on
the lst day after 5,6-0HT was followed by a gradual increase in activity until the 11th post-treatment day;subsequently, the locomotor activity began to decrease progressively.

This result can be construed as indicating a block

of the habituation response by the 5,6-0HT pretreatment and/
or as a recovery from the effect of 5,6-0HT treatment.
Similarly, in the repeated test design, the 6-0HDA treated
animals showed a depression of locomotor activity through
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the 19 days (Figure 3).

Since the activity levels de-

creased each day after 6-0HDA treatment it seems that
6-0HDA did not affect the habituation response (Figure
3) .

The spontaneous motor activity of the 6-0HDA treated

groups were significantly below that of vehicle treated
groups (p <. 0. OS) on each test day.

However, the 5, 6-0HT

treated groups were no longer significantly below vehicle
treated animals on the 5th and subsequent days

of testing.

Finally, in the repeated measure design, there were
no significant differences observed in the spontaneous
motor activity between the 6-0HDA or 5,6-0HT treated mice
on any post-injection day.

PHARMACOLOGICAL FINDINGS

LOCOMOTOR RESPONSE TO METHAMPHETAMINE - SINGLE TEST
PROCEDURE

The locomotor stimulation induced by 2.5 mg/kg of
methamphetamine, i.p., was significantly less in animals
-·.

that were pretreated with 6-0HDA as compared to vehicle
treated controls (Figure 4) •

This marked reduction in

activity was observed on the 1st (p 4C. 0. 005) as well as the
4th, lOth (p<.O.OS) and 20th (p<O.OOS) days following the
administration of 6-0HDA.

LOCOMOTOR RESPONSE OF 6-0HDA and 5,6-0HT TREATED
ANIMALS TO METHA11WHETAMINE CHALLENGE
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LEGEND FOR FIGURE' 4 •

The cumulated locomotor activity of mice was recorded
at 15 minute intervals for 90 minutes after methamphetamine
(2.5 mg/kg) administration on several days after treatment

with either ascorbic .acid vehicle (Asc), 6-0HDA or 5,6-0HT.
Different gr.oups of mice were employed on each day ( "sing.le
test"}.

Each point represents mean locomotor act.ivity of

3 groups of 6 mice.

S • E. M. values are shown for the cumu-

lated locomotor act.ivity at 90 minutes.
multiple range test

appli~d

The Newman-Keuls

to a 2 factor ANOV was used to

determine the significance of the diff·erences from control
values at 90 minutes.

The 5,6-0HT mice differed signifi-

cantly from controls on day 1, day 4 and day 20.

6-0HDA

treated animals differed sign.ificantly from controls on
each day tested (* p

~0.05,

**

p~O.Ol,

*** p L..005).

93
At certain times, the 5,6-0HT treated mice could be
differentiated from the 6-0HDA treated animals with regard
to their locomotor responses to methamphetamine.

The 5,6-

0HT treated mice were similar to the 6-0HDA treated mice in
their locomotor response to methamphetamine only on the
1st day following the intracerebral injection of the neurotoxins; in both

groups of animals locomotor stimulation

induced by methamphetamine was markedly reduced (p < 0. 005) •
However, on the subsequent testing days the 5,6-0HT treated
mice exhibited locomotor stimulatory effects, in response
to methamphetamine administration, which were greater than
those of 6-0HDA treated animals.

Additionally, on the 4th

and 20th days after the intracerebral injection of 5,6-0HT,
these animals exhibited an enhanced response to methamphetamine; i.e. this response was greater than that observed
in vehicle treated mice (p< 0.05 and<.O.Ol, respectively).
Those mice which had received intracerebral injections of
the ascorbic acid vehicle exhibited stable locomotor stimulatory responses to methamphetamine on each of the days
tested.

LOCOMOTOR RESPONSE TO METHAMPHETAMINE - REPEATED TEST
PROCEDURE

Figure 5 depicts the daily locomotor stimulation
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The cumulated locomotor activity of mice was recorded
at 15 minute intervals for 90 minutes· after methamphetamine
(.2.5 mg/kg) challenge on various days after. either ascorbic
'

'

'

acid. vehicle Asc 1 6-0HDA or

51

6-0HT. treatment.

The same

mice were tes.ted on alternate days ("repeated test").
Each point represents mean locomotor activity of 3 groups
of 6 mice.

A simple linear regression was fitted to the

data of each group;. r-square for the 5 1 6-0HT was 0.7804
(p /.. 0. 05).

Tolerance to methamphetamine did not occur on

this dose regimen s.ince the slopes. of the re·gression line
of both the vehicle treated and the 6-0HDA treated groups
were not significantly different from zero (i.e. the time
effect curve was parallel to the X axis).

The

5~6-0HT

treated mice differed significantly from controls on
days 1 thru 7; the response of 6-0HDA treated mice was
significantly less than that of the controls on each of
the days tested (p L 0 • 0 5) •
SEM of the activity.

The bar (I) represents + the
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induced by the i.p. administration of methamphetamine
(2.5 mg/kg) administered every other day to the same groups
of mice which were previously treated with either 6-0HDA,
5,6-0HT or vehicle.

The figure depicts these results as

linear regression curves fitted to the data by the least
squares method.

It is obvious that tolerance did not de-

velop in the vehicle treated mice to the locomotor stimulatory effects of methamphetamine as administered on this alternate days schedule; the slope of the regression line was
not significantly different from zero.

Thus, the vehicle

treated mice exhibited stable locomotor responses to methamphetamine in the repeated test procedure.
The 6-0HDA treated mice also exhibited stable locomotor responses to methamphetamine in the repeated test.
The stability is evidenced by the slope of the regression
line calculated for the 6-0HDA data, as the slope did not
differ significantly from zero.

As in the case of the

single test procedure, the 6-0HDA treated mice exhibited a
markedly diminished response to methamphetamine beginning
on the first day after 6-0HDA, and continuing throughout
the test period (p

< 0. 05) •

Similarly, the 5,6-0HT treated mice also exhibited a
marked reduction in their locomotor response to amphetamine on the 1st day after 5,6-0HT, substantiating the
results observed with the single test procedure.

However,
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the 5,6-0HT treated mice exhibited in the repeated test
procedure

a response to methamphetamine which gradually

approached that of the vehicle treated mice.

Specifically,

the 5,6-0HT treated mice exhibited on days 1, 3, 5 and 7 a
locomotor response to methamphetamine which was significantly less than that of vehicle treated mice; subsequently, there was no significant difference between

these two

groups.

LOCOMOTOR RESPONSE TO L-DOPA

The locomotor response of vehicle treated mice to
L-DOPA (100 mg/kg, i.p.) was unremarkable and constant on
each of the days tested (Figure 6).

However, 6-0HDA pre-

treatment resulted in a marked increase in the locomotor
response of mice to L-DOPA on the 1st, 4th, lOth and 20th
days after intracerebral 6-0HDA treatment

(p~O.OOl);

in

fact, 100 mg/kg of L-DOPA induced in 6-0HDA treated mice
wild running and jumping behavior.
In contrast to the 6-0HDA treated animals, the L-DOPA
response of the 5,6-0HT treated mice resembled that of the
vehicle treated mice.

Except for an occasional mouse which

exhibited some slight stimulation, the majority of 5,6-0HT
treated animals did not exhibit responses which were different from vehicle treated mice.

In fact, there were no
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LEGEND FOR FIGURE 6.
The cumulative locomotor activity of mice was recorded at 15 minute intervals after L-DOPA administration (100
mg/kg, i.p.) on various days following intracerebral injections of either ascorbic acid vehicle (Asc) , 70
6-0HDA, or 43

~gm

of 5,6-0HT.

~gm

of

The points represent the

mean locomotor activity of 3 groups of 6 mice each (n
under each treatment condition.

= 18)

S.E.M. values are shown

for the cumulative mean locomotor activity at 90 minutes
after L-DOPA.

The 6-0HDA and 5,6-0HT treated groups were

tested for significant differences from the vehicle treated
mice at 90 minutes after L-DOPA.

Asterisks indicate

significant differences with respect to vehicle treated
mice:

*

p~0.05;

**

p~O.OOl;

significance of differences

were determined with the Newman-Keuls multiple range test
applied to a ANOV.
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statistically significant differences between 5,6-0HT and
vehicle treated mice, in their locomotor response to L-DOPA
on any of the post-treatment days.

EVERETT TEST

Initial experiments (Barnes et al., 1973b) indicated that L-DOPA, 100 mg/kg, i.p. when administered 8 hours
after pargyline, 40 mg/kg, i.p., produced few signs in
vehicle treated mice (piloerection, exopthalmos, grade:l
Straub tail and a slight increase iri reactivity).

However,

L-DOPA administration to 6-0HDA-treated mice induced behavior previously described by Everett and Weigand (1962);
this behavior was characterized by hyperreactivity, squeaking, piloerection, exopthalmos, grade 3 Straub tail, spontaneous jumping and running; a few mice also exhibited aggression and/or stereotypic behavior.

It is important to

note that even when 6-0HDA treated animals exhibited a
marked depression of spontaneous motor activity e.g. on the
1st and 2nd days after intracerebral injection of 6-0HDA,
the administration of L-DOPA did not produce a return to
normal behavior, but rather the hyperreactive,hyperirritable
behavior described above (cf. Methods).

It was also ob-

served (Barnes et al., 1973b) that pargyline pretreatment
was not prerequisite for the response; accordingly, subse-
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TABLE 4
RESPONSE TO L-DOPA CHALLENGE IN 6-0HDA TREATED MICE
% OF POPULATION SHOWING THE RESPONSE

TIME AFTER
6 -OHDA TREATMENT .

GROUP

+1

+2

+3

4 Hr

Vehicle
6-0HDA

40
22

60
44

0
33

8 Hr

Vehicle
6-0HDA

50
7

40
7

10
86

16 Hr

Vehicle
6-0HDA

29
7

57
7

14
86

24 Hr

Vehicle
6-0HDA

40
0

40
29

20
71

2 Days

Vehicle
6-0HDA

70
0

30
0

0
100

10 Days

Vehicle
6-0HDA

100
0

0
10

0
90

20 Days

Vehicle
6-0HDA

80
6

20
35

0
59

30 Days

Vehicle
6-0HDA

100
0

0
25

0
75
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LEGEND FOR TABLE 4.
The average percentage of mice scoring +1, +2 or
+3 in response to L-DOPA 100 mg/kg, i.p. at various times
after 6-0HDA or vehicle treatment is tabulated.

The hyper-

sensitive response to L-DOPA was observed as soon as four
hours after intracerebral injection and seemed to be fully
developed by eight hours.

The response was evident through-

out the thirty day test period n= 16 per group at each
time after intracerebral injection.
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quent investigations were carried out without pargyline
pretreatment.
A time course evaluation was carried out to determine
at what point the exaggerated response to L-DOPA may be
demonstrated after intracerebral 6-0HDA; the results are
illustrated in Table 4.

The potentiation of the L-DOPA re-

sponse seemed evident as early as 4 hours following 6-0HDA
treatment; it was obvious and marked 8 hours after 6-0HDA.
The response persisted for at least 30 days following the
intracerebral injection of 6-0HDA (Table 4) •
A comparison was made between the L-DOPA responses
of vehicle, 6-0HDA and 5,6-0HT treated mice.

Mice typical-

ly exhibited a +1 response to L-DOPA whether tested 4, 10
or 20 days after the vehicle pretreatment; only infrequently did a vehicle treated mouse exhibit a response as high
as +2 (Table 5) .

The exaggeration of the Everett test fol-

lowing 6-0HDA pretreatment described by Barnes et al.
(1973b) was confirmed in the present experiments for the
4th, lOth and 20th days following the 6-0HDA treatment.

At

these times, from 92 to 100% of L-DOPA challenged 6-0HDA
treated mice exhibited a 3+ response.

This difference in

response of 6-0HDA and vehicle treated mice was statistically significant (Table 5) •
The response to L-DOPA of 6-0HDA pretreated animals
differed from that recorded in the 5,6-0HT treated animals.
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TABLE 5
RESPONSE TO L-DOPA IN. 5,, 6-0HT OR 6-0HDA TREATED MICE
DAYS AFTER
INTRAc;EREBRAL
INJECTION

PERCENT OF POPULATION
SHOWING THE RESPONSE
+2
+1
+3

GROUP

4

Vehicle
5,6-0HT b)
6-0HDA . a)

100
83
0

0
17
8

0
0
92

10

Vehicle
5,6-0HT b)
6-0HDA a)

75
42
0

25
33
0

0
25
100

20

Vehicle
5,6-0HT b)
6-0HDA a)

67
42
0

33
42
0

0
17
100

The percentages (rounded off to the nearest whole
number) represent the number of animals meeting the criteria described in the methods.

N=24 for each group.

The

differences between test scores of 6-0HDA and 5,6-0HT
treated mice and their controls were evaluated for statistical significance by the Chi-squared statistic.

a) In

the case of 6-0HDA treated mice the null hypothesis was
rejected for the fourth (p

< 0.0005,

tenth (p ( 0.0005, d.f. = 2, x

2

d. f. = 2, x 2 = 48),

= 23), and twentieth (p<

0.0005, d.f. = 2, x 2 = 23) day after intracerebral injection.

b) In the case of 5,6-0HT treated mice the null

hypothesis was accepted for the fourth (p < 0. 2, d. f. = 2,
x 2 = 4.4), tenth (p (0.2, d.f. = 2, x 2 = 4.3) and twentieth (p .£, 0. 2, d. f. = x
injection.

2

= 2. 3) day after intracerebral

105
While there was a mild increase of the irritability following L-DOPA administration in 5,6-0HT treated animals, only
on the lOth and 20th day following such treatment was a 3+
response noticed in a small, 17 to 25%, segment of the population; however, the differences between the L-DOPA responses of the 5,6-0HT and the vehicle treated animals were
not statistically significant (Table 5).

Thus, 6-0HDA

treatment, but not vehicle or 5,6-0HT treatment induced a
significant supersensitive response to L-DOPA.

This sug-

gests that a greater change in the catecholaminergic system
was induced by 6-0HDA than by 5,6-0HT treatment.

EVERETT TEST AFTER DECARBOXYLASE INHIBITION

RO 4-4602, an aromatic amino acid decarboxylase inhibitor (Pletscher and Bartholini, 1971) interfered with
the response of the 6-0HDA treated mice to L-DOPA as evaluated by the Everett test (Table 6) •

The response was block-

ed by RO 4-4602 at the En 50 dose of 70 (95% confidence
limits 42-117) mg/kg; at this dose, 50% of animals showed
only a 1+ or 2+ response to L-DOPA.

A 25 mg/kg, i.p., dose

of RO 4-4602, which presumably blocked only peripheral
decarboxylase and not central decarboxylase, did not inhibit
the response to L-DOPA of 6-0HDA treated mice.

EVERETT TEST SCORES OF 6-0HDA TREATED MICE AFTER
AND VARIOUS DOSES OF R04-·4602
DOSE OF R04-4602
IN MG/KG

L-DO~A

% OF ANIMALS SHOWING SCORES OF
+3
+1
(n)
+2

0

75%

8%

17%

12

25

100%

0%

0%

12

50

41%

41%

17%

12

100

55%

36%

9%

11

200

10%

72%

18%

11

400

16%

50%

34%

12

1-'
0
0'1

800
TABLE 6.

0%

64%

36%

11

Seventy micrograms of 6-0HDA were given intracerebrally to all

mice 45 days prior to L-DOPA.
30 minutes prior to L-DOPA.

R04-4602/l was administered intraperitoneally
L-DOPA (100 mg/kg) was administered intraperi-

toneally and observations were made 30 minutes later.

The Eo

50

and 95% con-

fidence limits for blockade of the +3 response by R04-4602 was 70 (42-117)
mg/kg.
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RESPONSE TO APOMORPHINE

A supersensitive response to apomorphine consisting
of spontaneous jumping behavior and/or hyperreactivity (cf.
Methods) was induced in a large percentage of mice treated
with 6-0HDA; this supersensitivity was observed on all 3
days of testing (Table 7) •

The observed differences be-

tween the number of 6-0HDA treated and vehicle treated mice
exhibiting supersensitivity (hyperactivity and spontaneous
jumping, cf. Methods) were statistically

signif~cant

on the

4th (p '0. 01) , lOth (p<O. 0005) , and 20th days (p < 0. 01)
following intracerebral injection (Chi squared statistic) •
The administration of apomorphine resulted, particularly in
the case of 6-0HDA pretreated mice in spontaneous jumping
and hyperactivity ( the mice exhibited jumping and kicking
on introduction of a foreign object) .

Other signs observed

in mice after apomorphine included a rigid gait, mouthing
of sawdust, and stereotypic climbing on the wire top of
the cage (cf. Methods).
The 5,6-0HT pretreated animals also showed a supersensitive response to apomorphine.

However, fewer 5,6-0HT

than 6-0HDA treated mice exhibited spontaneous jumping behavior following apomorphine.

The differences between the

number of vehicle and treated mice exhibiting the supersensitivity was significant in the case of 5,6-0HT treated
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TABLE 7

RESPONSE TO APOMORPHINE IN 5,6-0HT OR 6-0HDA TREATED MICE

DAYS AFTER
INTRACEREBRAL
INJECTION

GROUP

PERCENT OF GROUP EXHIBITING
SUPERSENSITIVITY AS *:
SPONTANEOUS
HYPERJUMPING
REACTIVITY

4

Vehicle
5,6-0HT a)
6-0HDA b)

0
41
45

16
26
28

10

Vehicle
5,6-0HT a)
6-0HDA b)

0
33
91

8
42
0

20

Vehicle
5,6-0HT a)
6-0HDA b)

0
33

16
17
35

55

* The remaining mice did not exhibit a supersensitive response to apomorphine.
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LEGEND FOR TABLE 7.

The table shows the proportion (in percent) of mice
exhibiting either jumping and hyper.re.activity, or only
hyperreactivity at various days following the vehicle,
6-0HD.A or 5, 6-0HT treatment.

Twe~ve

mice were employed

in each test.
The differences between the numbers of mice exhibiting supersensitivity (hyperreactivity alone or jumping as
well as hyperreactivity) to apomorphine af.te.r 5, 6-0HT or
6-0HD.A and vehicle treatment were evaluated for statistical
significance by the Chi-squared statistic.

a) The null

hypothesis that .the differences following 5,6-0HT were due
to chance was rej.ec.ted for the 4th (pL0.025, d.f. = 1,
x2 = 6.2) and lOth (p~O.OOl, d.f. = 1, x 2

= 11.0) days
1, x 2

but accepted for the 20th day (p ::> 0 .1, d. f.

=

after intracerebral injection.

hypothesis

b) The.

nul~

=

3. 0)

that the observed differences following. 6-0HDA were due to
chance was rejected for the 4th (pL.O.Ol, d.f. = 1, x 2 =
7.3} lOth (pL.O.OOOS,. d.f. = 1, x2 = 15-.7) and. 20.th days

~LO.Ol, d.f.

= 1,

x2

= 7.3).
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animals on the 4th (p (. 0. 025) and lOth (p-< 0. 001) days but
not on the 20th day.

The percentages of responding animals

were always greater in the case of 6-0HDA than in that of
5,6-0HT treated mice.

RESPONSE TO TREMORINE

A tremorigenic response was present after tremorine
(10 mg/kg, i.p.) in vehicle treated mice (Table 8).

The

peak tremor response was-observed at 15 minutes after injection.

There were no significant differences among the

mean tremor responses observed in the vehicle treated mice
on any of the 3 days tested.
On the 4th day after intracerebral injection of
6-0HDA the tremorigenic response to tremorine was significantly increased.

As in the case of the vehicle treated

mice the peak tremor response in the 6-0HDA treated mice
occurred 15 minutes after tremorine administration.

How-

ever, this increased response to tremorine was not observed
on the lOth and 20th days after 6-0HDA treatment (Table 8) •
The peak tremor response was induced by tremorine 15
minutes after its administration to the 5,6-0HT treated
mice as was the case with vehicle or 6-0HDA treated mice.
Similar to the 6-0HDA treated mice, the 5,6-0HT treated
mice exhibited an enhanced tremor response to tremorine on

TREMORIGENIC RESPONSE TO TREMORINE
DAYS AFTER
INTRACEREBRAL
INJECTION
4

10

20

TABLE 8.

GROUP
Vehicle
6-0HDA
5,6-0HT
Vehicle
6-0HDA
5,6-0HT
Vehicle
6-0HDA
5,6-0HT

AVERAGE NUMBER OF INTEGRATOR
RESETS PER MINUTE + S.E.
8.64 + 3.73 (9)
21.25 + 8.90 (4)
26.24 + 8.93 (5)

(a)
(b)

6.66 + 1.12 (17)
6.98 + 4.58 (4)
9.89 + 2.73 (13)
7.82 + 1.96 (17)
- 1.49 (8)
6.80 +
13.38 + 3.09 (9) (a)

P VALUE

< 0.05

< 0. 025

N.S.
N.S.

N.S.
.( 0.05

The average number of integrator resets per minute was cal-

culated for each group 15 minutes after tremorine (10 mg/kg, i.p.).
tistical significance was determined by the Mann Whitney U test.
means not significant.

Sta-

N.S.

112
the 4th day after intracerebral injection (p <. 0. 025). · However, unlike the 6-0HDA treated mice, the 5,6-0HT treated
mice also exhibited an enhanced tremor response on the 20th
day following intracerebral injection (p

< 0. 05) •

On the

lOth day after injection, the 5,6-0HT also exhibited an
apparent enhanced tremor response to tremorine, but this
response was not great enough to be statistically significant.

Thus, 6-0HDA and 5,6-0HT treated mice were similar

in their response to tremorine only on the 4th day after
intracerebral injection, whereas 5,6-0HT treatment appeared
to induce a longer lasting enhancement of the tremor response to tremorine than did 6-0HDA treatment.

The onset

of tremors was not significantly changed in any of the
groups on any of ·the days tested.

RESPONSE TO L-5-HTP

L-5-HTP, 200 mg/kg, i.p., induced a verJ mild tremorigenic effect in vehicle treated animals.

The effect was

relatively stable with no clear peak effect.

In contrast,

mice which received an intracerebral injection of 6-0HDA
exhibited a greatly enhanced tremorigenic response to 5-HTP
(Table 9) on the 4th (p <.0.05), lOth (p
(p

< 0. 005) days after 6-0HDA treatment.

~

0.01) and 20th
Only on the 4th

post-treatment day was the onset of tremors in 6-0HDA

TABLE 9
TREMORIGENIC RESPONSE TO 5-HTP
DAYS AFTER
INTRACEREBRAL
INJECTION

MINUTES
AFTER
L-5-HTP

4

30

P VALUE

12.2 + 4.72
18.2 + 2.79

(10)
(5)

~

Vehicle
5,6-0HT

3.38 + 1.74
11.36 + 2.76

(5)
(5)

.{.. 0.05

Vehicle
6-0HDA

4.97 + 2.09
28.17 + 7.45

(6)
(3)

.( 0.01

Vehicle
5,6-0HT

(8)
2.92 + 0.96
39.64 + 18.72 (4)

.( 0. 025

30

Vehicle
6-0HDA

4.91 + 1.66
18.53 + 3.05

{9)
(3)

< 0. 005

5

Vehicle
5,6-0HT

4.49 + 1.39
22.11 + 6.39

{11)
(7)

<0. 025

30
5

20

AVERAGE NUMBER OF INTEGRATOR
RESETS PER MINUTE + S. E.

Vehicle
6-0HDA

5
10

GROUP

0.05

~
~

w
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· LEGEND: F"OR TABLE :g •

Tremorigenic response to L-5-HTP .(200

~g/kg,

i.p.)

was quantified for mice on various days -after the intraceJ;ebral injection of. vehicle, 6-0HDA or 5·,6-0HT.

The peak

res.ponse in 6-0HDA treated mice occurred 30 minutes after
5-HTJ?, while that of 5,6-0HT treated mice occurred: 5
minutes after 5-HTP.

Significance of. dif.ferences was de-

termined by the Mann Whitney u test.

12 MINUTES AFTER 5- HTP
ASCORBIC

6-0HDA

5,6-HT
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LEGEND FOR FIGURE 7.
The upper tracing illustrates the unintegrated
recording of tremor activity in treated mice fifteen
minutes after L-5-HTP administration on the fourth day
after intracerebral injection of vehicle, 6-0HDA or
5,6-0HT (REC).

The lower tracings represent the in-

tegrated activity (INTG.) of the upper tracing which
was used in quantifying the data.

Significance of

differences were based upon the mean number of integrator resets per minute determined for selected five
minute periods.

Ten seconds of recording are illustrated.
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treated mice significantly more rapid than the onset in the
vehicle treated mice (1.6 minutes versus 4.1 minutes,
p<0.05).

The peak tremor response in 6-0HDA treated mice

occurred 30 minutes after L-5-HTP.
5,6-0HT treatment also markedly increased the response to L-5-HTP on the 4th (p < 0. 05) , lOth (p <. 0. 025) and
20th days (p <. 0. 025).

The onset of tremors was more rapid

only on the 4th day after 5,6-0HT treatment (2.1 minutes
versus 4 .1 minutes for controls, p <. 0. 0 5) •

Thus, mice

which were treated with either 6-0HDA or 5,6-0HT exhibited
a marked potentiation of the tremorigenic effect of L-5-HTP
on each of the days tested; in this case, the two neurotoxins
were indistinguishable at the doses employed.

Figure 7 il-

lustrates the actual recordings of the tremor responses to
5-HTP obtained in a typical experiment.

RESPONSE OF 5,6-0HT TREATED MICE TO L-5-HTP AFTER DECARBOXYLASE INHIBITION

The decarboxylase inhibitor affected in a biphasic
fashion the response to 5-HTP challenge of mice pretreated
with 5,6-0HT.

At the dose of 25 mg/kg, RO 4-4602 increased

significantly (p<.0.05) the incidence of intermittent tremor (Table 10) and spread eagle response in the 5,6-0HT
treated animals as compared to vehicle treated mice or mice
treated with the vehicle and RO 4-4602; at the dose of

~~MPTOMOLOG~

DOSE OF
R04-4602
IN MG/KG

GROUP

IN 5,6-0HT TREATED MICE AFTER L-5HTP AND
VARIOUS DOSES OF R04-4602/l

FLUSHED
EARS AND
PAWS

HEAD SHAKING

INTERMITTANT
TREMORS

SPREAD
EAGLE

DEATH

0
0

ASC
5,6-0HT

7/7
6/6

6/7
6/6

2/7
3/6

0/7
3/6

0/7
3/6

25
25

ASC
5,6-0HT

0/6
0/6

0/6
6/6

0/6
6/6

0/6
0/6

0/6
0/6

800
800

ASC
5,6-0HT

0/4
0/6

0/4
0/6

0/4
0/6

0/4
0/6

0/4
0/6
I-'
I-'
00

TABLE 10.

All mice received R04-4602/l 30 minutes before L-5HTP.

servations were made for one hour following L-5HTP.
tered i.p.

All

~ice

received 43 Agm/10

~1

Ob-

R04-4602/l was adminis-

of 5,6-dihydroxytryptamine (5,6-0HT)

or 10 ul of a l:lOOO.aqueous ascorbic acid vehicle (ASC) 45 days prior to
L-5HTP (200 mg/kg, i.p.).
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800 mg/kg,

RO 4-4602 decre·ased significantly (p.(. 0.005}

the incidence of these responses as well as of the head
shaking response.

On the other hand, at both 25 and 800

mg/kg dose, RO 4-4602 blocked completely the appearance of
the peripheral response to 5-HTP, the flush of ears and
paws, in both vehicle and 5,6-0HT treated mice.

DISCUSSION

NEUROCHEMICAL FINDINGS WITH 6-0HDA

This study compares the effects of two neurotoxic compounds, 5,6-0HT and 6-0HDA, for their selectivity of action.
Selectivity was assessed by measuring the brain contents of
four neurotransmitters: DA, NE, 5-HT and ACh.

Furthermore,

the permanence of the neurotoxic sequelae were also evaluated in terms of pharmacological and behavioral responses of
5,6-0HT and 6-0HDA treated animals to challenges with appropriate drugs and precursors.
As a catecholamine congener, 6-0HDA might be expected
to affect brain catecholamines to a greater extent than
brain indolamines (Malmfors and Thoenen, 1971) .

In fact,

it was observed that 6-0HDA was taken up more selectively by
catecholaminergic rather than indolaminergic terminals of
the rat brain (Heikkela and Cohen, 1973).

Thus, it was ex-

pected that the uptake of 6-0HDA by catecholaminergic neurons would result in their selective destruction as de- ·
scribed by Javoy et al. (1976).

The marked declines in the

brain contents of NE and DA after 6-0HDA indicated that
a lesion of catecholamine neurons occurred (cf. Table 1).
It was reported that very similar catecholamine depletion
120
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occurred after 6-0HDA in the rat (Breese and Traylor, 1970).
Aromatic amino acid decarboxylase is an enzyme which
can synthesize dopamine from L-DOPA (Levine and Sjoerdsma,
1964) •

Our data indicate that the activity of aromatic

amino acid decarboxylase is not significantly reduced by
6-0HDA because even after 6-0HDA the brain content of DA can
I

still be elevated by L-DOPA (Table 3).

Similarly, 6-0HDA

treatment did not affect the decarboxylation of L-5-HTP to
5-HT (Table 3) •

Similar results were also reported in rats

treated with 6-0HDA

(Urets~y

and Schoenfeld, 1971).

However, there occurred after 6-0HDA (70 Agm/10

~1)

treatment a significant reduction in the brain content of
5-HT.

The reduction in 5-HT content was still evident at

20 days post treatment.
action for 6-0HDA.

This indicates a non selective

Thus, it appears that the present method

cannot be utilized in mice to achieve a total selective lesion of central catecholaminergic neurons.

The decrease in

the brain 5-HT content has been previously reported by some
(Bloom et al., 1969) and denied by other investigators
{Uretsky and Iversen,

1970~

Jacks et al., 1972).

According

to our data 6-0HDA was only relatively selective at the dose
employed in the mouse as it induced a greater depletion of
DA and NE than of 5-HT.

It must be emphasized that most in-

vestigators measured 5-HT at 21 days or later, after 6-0HDA
administration and may have missed earlier unselective ef-
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fects of 6-0HDA on brain 5-HT levels (Bloom et al., 1969;
uretsky and Iversen, 1970).
Altogether, our data suggest that 6-0HDA is not taken
up selectively by catecholaminergic neurons as indicated
also by neurochemical and histochemical evidence (Fuxe and
Ungerstedt, 1968; Fozard and Clarke, 1970; Iversen, 1970).
At the dose of 6-0HDA employed, 6-0HDA appeared to be only
relatively

sel~ctive

in its action in the mouse; alterna-

tively, a functional change may have occurred in the serotonergic system following 6-0HDA treatment and this may have
resulted in the decreased 5-HT levels.

NEUROCHEMICAL FINDINGS WITH 5,6-0HT

At the intracerebral dose employed, 43

~gm/10

/;(. 1,

5,6-0HT induced marked (up to 53%) and prolonged diminution
of mouse brain levels of 5-HT.

This effect was comparable

to that obtained by others (Bjorklund et al., 19741 Saner et
al., 1974).

The action was not entirely specific as NE and

DA levels were also significantly diminished; however, the
action of 5,6-0HT on catecholamines was less pronounced and
brief compared to its action on 5-HT.

Longo et al.

(1974)

who used doses essentially identical with ours reported effects of 5,6-0HT on DA content similar to those obtained by
us; on the other hand, the changes in NE content which they

12J
reported were variable.

Changes in brain DA and/or NE con-

tent were also obtained by Bjorklund et al. (1974) with
intraventricular administration and by Breese et al. (1974b)
with intracisternal administration of 5,6-0HT.

Also, Saner

et al. (1974) who injected 5,6-0HT into median forebrain
bundle noticed a considerable decrease in DA of the rat
telencephalon; a similar lack of specificity of 5,6-0HT was
reported by Baumgarten et al.

(1972~,1973).

It should be emphasized that the depletions of NE and
DA which were observed in this study after 5,6-0HT were of a
transient nature since the brain content of these catecholamines was not significantly different from that of the
vehicle treated mice on the lOth and 20th days after 5,6-0HT
treatment (Table 1).

Thus, in our hands 5,6-0HT may have a

relatively selective effect on the serotonergic system in
the mouse, as the catecholamines recovered from their initial depletion while the 5-HT content remained depleted.
Furthermore, 5,6-0HT treatment did not inhibit the capacity
of the brain to synthesize catecholamines and serotonin from
systemically administered L-DOPA and L-5-HTP, respectively
(Table 3).

Finally, 5,6-0HT treatment did not alter the

resting level of ACh in mouse brain at any time tested.
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INTERACTIONS BETWEEN THE DOPAMINE'RG'IC ,
CHOLINERGIC AND SEROTONERG'IC SYSTEMS.

The ability of anticholinergic agents to reverse the
tremor and rigidity of Parkinsonian patients is well known.
Also well recognized is the effectiveness of anticholinergic
agents in the treatment for drug induced extrapyramidal reactions.

However, the role of dopamine in these conditions

was not emphasized until the pathological and neurochemical
etiology of Parkinson's Disease was identified as a deficiency of striatal dopamine (Hornykiewicz, 1966, 1973).
As a consequence of th{s discovery an interrelationship between striatal cholinergic and dopaminergic systems was envisioned and extensively studied.

The resultant experimen-

tation has generally supported such an interrelationship.
The following discussion will first indicate those experiments which support the concept of a dopaminergic cholinergic interaction; second, it will indicate recent findings
with 6-0HDA which are quite unexpected and which may require
a slight revision of the concept.
Several investigations suggest that nigral dopaminergic neurons exert a tonic inhibitory effect on striatal
cholinergic neurons.

For example, Sethy and Van Woert

(1974 a, b) reported that dopamine receptor stimulation with
dopamimetics diminishes ACh release and increases striatal
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ACh content.

Conversely, they reported that dopamine re-

ceptor blockers increase ACh release and decrease striatal
ACh content.

Similar findings were reported by Consolo et

al.

Furthermore, dopamimetics reduce ACh turnover

(1974b).

in striatum (Trabucchi et al., 1975a). In contrast, DAreceptor blockers increase striatal ACh turnover (Trabucchi et
al., 1974).

Nigral stimulation induces a release of DA in

the striatum (Portig and Vogt, 1969) as well as inhibits
unit activity in the caudate (Connor, 1970; Krnjevic, 1975).
Moreover, transection of the nigrostriatal pathway diminishes DA release from the ventricular area of the caudate
nucleus (Besson et al., 1974).

Thus, if the nigrostriatal

dopaminergic system exerts a physiological tonic inhibition
of striatal cholinergic cells, it may be expected that
diminution of the presynaptic supply of DA should result in
enhanced cholinergic function in the striatum.
of dopamine synthesis by means of

~-mpt,

Inhibition

or nerve terminal

destruction by means of 6-0HDA or lesions of the nigrostriatal pathway were used to decrease the presynaptic DA
content; the results of these studies are discussed below.
Surprisingly, the literature which describes the effects of

~-mpt,

nigrostriatal pathway lesions, or 6-0HDA

treatment on striatal cholinergic function remains controversial.

For example, Beani and Bianchi (1973) reported the

expected increase in striatal ACh after o(-mpt treatment.
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gowever, two other groups found Dl-mpt to be without
effect on striatal ACh levels (Jones et al., 1973; Guyenet
et al., 1975a).
The effect of nigrostriatal pathway lesions on striatal function also is surprising.

Such lesions did not alter

the activity of choline acetyltransferease or acetylcholinesterase in the brains of either rats (Me Geer et al.,
1973) or baboons (Katoaka et al., 1974).
Furthermore, most investigations which employed 6-0HDA
to diminish the presynaptic supply of DA, found 6-0HDA to be
without effect on striatal cholinergic function.
stance, Consolo et al.

For in-

(1974a) found that 6-0HDA did not af-

fect either ACh levels or choline acetyltransferase activity
of rat striatum.
al.

(1974).

Similar results were obtained by Grewal et

Furthermore, 6-0HDA treatment did not alter the

choline acetyltransferase activity of either rat striatum
(Kim, 1973), substantia nigra (Me Geer et al., 1973) or
mouse cortex (Kostrzewa, 1973).

Kim's (1973} findings did

not agree with the others since he reported after 6-0HDA a
marked elevation of rat striatal ACh as well as a decrease
in acetylcholinesterase activity in rat striatum; however,
Kim's report (1973} was not confirmed by others.
It is also interesting to note that 6-0HDA treatment
did not enhance the increase in striatal ACh utilization
induced by dopamine receptor antagonists (Stadler et al.,
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1973).

Conversely, 6-0HDA treatment did not antagonize the

diminution of ACh utilization induced by dopamine receptor
agonists (Ladinsky et al., 1975).

Lastly, and even more

surprising is the fact that the inhibitory effect of nigral
stimulation is not inhibited by 6-0HDA treatment (Krnjevic,
19 7 4) •
In summary, directly acting DA receptor agonists have
consistent effects on striatal ACh; the effects of indirectly acting DA receptor agonists on striatal ACh remain controversial.

Thus, it appears that not all problems have

been resolved in establishing a concept of a physiological,
dopaminergic,tonic inhibition of striatal cholinergic cells.
Since the ·brain part that we analyzed contained the
striatum, our data have relevance to the concept of a striatal dopaminergic cholinergic interaction.

Basically, nei-

ther 6-0HDA nor 5,6-0HT changed endogenous ACh levels (Table
2).

The data with 6-0HDA are in direct agreement with those

of Jacks et al.

(1972) and Consolo et al.

with 5,6-0HT are novel.

(1974a).

The data

Our data with 6-0HDA contributes to

a growing body of evidence which suggests that 6-0HDA treatment is without effect on striatal ACh levels.
Furthermore, our own data and those of others (cf.
above) suggest that excessive DA receptor stimulation rather
than tonic DA receptor stimulation inhibits striatal ACh
utilization.

This latter statement may be supported by the
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results of Agid et al.

(1975) who demonstrated again that

6-0HDA alone did not reduce striatal ACh levels; however,
6-0HDA did inhibit the increase in striatal ACh levels induced by a high dose (10 mg/kg) of amphetamine.
In an attempt to put the 6-0HDA data in line with the
hypothesis of a tonic inhibitory action of DA on striatal
ACh cells the following hypotheses may be considered.

It

may be argued that we did not achieve sufficient depletion
of DA to modify cholinergic function.
al.

However, Guynet et

(1975a) achieved after 6-0HDA a DA level of only 5% of

normal, without being able to detect alterations in ACh content.

It may also be argued that the dopaminoceptive cho-

linergic neurons may only be a small percentage of the total
population of cholinergic neurons in striatum.

Alternative-

ly, it may also be argued that after 6-0HDA a quasi-normal
state of cholinergic function could be maintained by supersensitive DA receptors.

Obviously, further studies of the

interaction of the dopaminergic system on the cholinergic
system with respect to both levels and turnover values of
acetylcholine, after presynaptic alterations of the nigrastriatal pathway (Costa and Neff, 1968) ,are needed for the
resolution of this important point.
Also related to this matter of a dopaminergic cholinergic interaction are our results following L-DOPA treatment.

Our results indicate that L-DOPA administration to

129
either vehicle, 6-0HDA or 5,6-0HT treated animals, and the
resultant increase in the level of DA, did not affect brain
ACh levels.

Similarly, Sethy and Van Woert (1973) found no

change in rat brain ACh levels with a single administration
of L-DOPA but a small (8-13%) increase in ACh content was
observed with chronic L-DOPA.

The lack of effect of L-DOPA

on neostriata! levels of ACh was also reported by others
(Beani et al.,

1966~

Beani and Bianchi, 1973).

It was re-

cently reported that a decarboxylase inhibitor may be necessary to demonstrate acute effects of L-DOPA on the striatal cholinergic neurons (Sethy and Van Woert, 1974 a, b).
This later result appears to be a sufficient explanation of
the present results.

In summary, since 6-0HDA did not reduce

brain ACh content, we may conclude that 6-0HDA did not
destroy central cholinergic neurons.

The results of others

(cf. above) also lead to a similar conclusion.
However, the results obtained with tremorine appear
inconsistent with respect to this concept.

An enhanced re-

sponse to tremorine was observed on the fourth, but not on the
tenth or twentieth days after 6-0HDA.

The enhancement of the re-

sponse to tremorine on the 4th day suggests a supersensitivity
of cholinergic receptors.

At least three other published hy-

potheses may be related to this result.

The first is that

6-0HDA induced a diminution of DA and resulted in a

dis-

inhibited cholinergic state (see previous discussion}.
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The second is that striatal cells become more sensitive to
ACh or to muscarinic agonists, following the loss of DA as
suggested by Spehlmann (1975) •

The third is that the super-

sensitive response to tremorine was indirect and mediated by.
the 6-0HDA induced supersensitivity of the catecholaminergic
system (Tables 4, 5, 7).
To expand upon and to explain the last hypothesis, several studies suggested that the cholinergic system may exert
its effects by means of the catecholaminergic system.
instance, the

For

antirecruitment effects of the anticholines-

terase, physostigmine, requires a non-depleted pool of catecholamines (Van Meter and Karczmar, 1971).

Furthermore, in-

creases in ACh levels can induce an increase in DA and a decrease in NE levels (Glisson et al., 1972).

This latter ef-

fect may occur in the case of both a normal or a particularly increased supply of catecholamines (Glisson et al., 1972,
1974).

Moreover, oxotremorine, a muscarinic agonist, in-

creases striatal DA content (Javoy et al., 1974 a, b).

Fi-

nally, the locomotor stimulatory effects of anticholinergic
compounds, even those which do not block DA uptake (Coyle
et al., 1969), are dependent upon a presynaptic supply of
dopamine (Thornburg and Moore, 1973 a, b).
While any one of these hypotheses may explain the enhanced response to tremorine on the 4th day after 6-0HDA,
they do not explain the lack of an increased response to
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tremorine on the lOth and 20th days after 6-0HDA. The latter result may be explained as a long term accommodation of
cholinergic function which occurs in response to an acute
6-0HDA induced perturbation of cholinergic function (Agid et
al., 19 75) •
In summary, since 6-0HDA treatment did not induce a
decrease in brain ACh levels nor did it induce a long term
supersensitivity to tremorine, it may be concluded that
6-0HDA did not induce a lesion of cholinergic neurons.

In-

stead, the transitory increased response to tremorine on the
4th day may reflect a 6-0HDA induced alteration in neurotransmitter system interactions.

Obviously, much additional

research would be required to adequately resolve this complex issue.
A special consideration should be given to the novel
results obtained with respect to an interaction between
5-HT and ACh.

While the diminution of 5-HT levels by the

5,6-0HT treatment did not affect ACh levels, the latter were
markedly increased following the 5-HTP challenge of the control and 6-0HDA treated mice.

However, the 5-HTP challenge

did not increase the levels of ACh in the 5,6-0HT pretreated
mice.

The results indicate that 5-HTP may increase the ACh

levels only in the presence of relatively intact serotonergic neurons as in the case of the ascorbic acid or the 60HDA treated animals.

Somewhat similar conclusions were
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reached by Pepeu et al.(l974a) who demonstrated an increase
in ACh release after a 5-HTP administration to parachlorphenylalanine treated rats, but not in rats with lesions of
the raphe nuclei.
A serotonergic-cholinergic interaction has also been
suggested by the observation of parallel decreases in both
ACh and 5-HT levels in animals with septal lesions (Heller
et al., 1962).

Recently, Barnes et al.

(1974) have shown

that central accumulation of ACh leads to marked increases
of 5-HT in several brain parts.

The data of Haubrich and

Reid (1972) also support the concept of a serotonergiccholinergic interaction as they reported an increase in 5-HT
turnover following muscarinic agonists.

Furthermore, the

serotonomimetic agent, quipazine, raises striatal ACh levels; this effect is considered to be mediated through the
serotonergic system (Euvrard et al.,l977). Harmaline,a monomine oxidase inhibitor of indole derivation, increases
striatal ACh levels.

The effect is not mediated by an in-

teraction with the dopaminergic or gabaminergic systems.

It

also appears that the effect of harmaline may not be mediated through the serotonergic system (Javoy et al., 1977).
T~us,

although evidence is accumulating for a serotonergic-

cholinergic interaction there may be even other neurotransmitter cholinergic interactions in striatum which are still
to be identified.

Altogether, the data of others as well as
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our own suggest that the serotonergic and cholinergic
systems may affect each other's function.
Evidence exists which suggests that the dopaminergic
and serotonergic systems also interact.

L-DOPA has been

shown to cause a reduction in brain 5-HT content (Everett
et al., 1970; Bartholini et al., 1968; Butcher et al.,
1969).

A serotonin depleting effect of L-DOPA was also

observed in this study (Table 3).

Moreover, this effect of

L-DOPA on brain 5-HT is attenuated by 6-0HDA treatment as
shown by Algeri et al.
as well (Table 3) •

(1974) and as observed in this study

The L-DOPA induced inhibition of spon-

taneous motor activity and the hypothermia were attributed
to the release of cerebral 5-HT stores (Maj et al., 1971,
1973, 1974).

Furthermore, 6-0HDA and oL-mpt (Jouvet et al.,

1973) were shown to increase 5-HT turnover in brain.
Some data also indicate that L-DOPA-serotonin interaction exists in man as the lumbar cerebrospinal fluid
levels of 5-HIAA were elevated following L-DOPA treatment
(Chase, 1974).

In fact, an inverse correlation exists be-

tween the degree of akinesia and rigidity in Parkinsonism
and the degree of 5-HT depletion (Chase, 1974).

However,

the addition of PCPA to L-DOPA treatment of Parkinsonism did
not affect the therapeutic efficacy (Chase, 1974).

More re-

cently, apomorphine was reported to increase the turnover of
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orain 5-HT (Grabowska, 1974).

To the contrary, another

dopaminergic agonist, ET 495, was without affect on the rat
brain levels of 5-HT or 5HIAA (Consolo et al., 1975).

These

findings merely illustrate the complexity of interpretation
of neurotransmitter interactions and the need for additional
research to identify functional relationships between these
neurotransmitter systems.

In summary our data support the

reported L-DOPA induced depletion of 5-HT and also confirms
the reported impairment of this effect by 6-0HDA treatment.

PHARMACOLOGICAL AND BEHAVIORAL RESULTS AND THEIR RELATIONSHIP TO THE 5-HT, ACh AND CATECHOLAMINE SYSTEMS

RELEVANCE OF THE EFFECTS OF 6-0HDA AND 5,6-0HT ON LOCOMOTOR ACTIVITY TO THE FUNCTIONAL STATE OF BIOAMINE SYSTEMS

While the opinion was not unanimous, 6-0HDA was reported to cause behavioral and locomotor depression (Cooper
et al., 1973) as it did in this study.

There were relative-

ly few studies of the locomotor effects of 5,6-0HT; the
results of Longo et al. (1974) and the present as well as
our earlier data (Barnes et al., 1973 a, c» indicate that
this compound markedly decreased motor activity, contrary to
the non-quantified data of Baumgarten et al.
Prada (1972) and Longo et al. (1974).

(1972b), Da

On the other hand,
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disinhibitory or excitatory effects of 5,6-0HT were more in
keeping with the opinion held by many since the early suggestion of Brodie and Shore (1957) that 5-HT was a behavioral suppressant; indeed, some of our own data {cf. below) may
be consistent with this concept.
The 5,6-0HT treated animals while exhibiting initially
a depression of locomotor activity, showed subsequently some
recovery in the continuous test paradigm as their locomotor
activity was no longer significantly depressed, compared to
the controls, after the fifth post-treatment day (Figure 3).
On the other hand, when the single test procedure was employed the motor activity of the 5,6-0HT treated group remained depressed through the tenth post-treatment day
(Figure 2) •

The apparent earlier recovery of motor activ-

ity in 5,6-0HT treated mice in the repeated test may be explained as follows.

The vehicle treated animals show habit-

uation to the cage and exhibit, in repeated tests, a progressive reduction in locomotor

activity~

this habituation

may not have occurred in the 5,6-0HT treated mice.

Indeed,

the locomotor activity of the vehicle treated mice progressively decreased and by the 5th day approached the level exhibited by the 5,6-0HT treated mice.

The 5,6-0HT treated

mice eventually did exhibit habituation but only after the
11th day; interestingly, exploratory activity returned to
normal at this time in the single test procedure.

Thus, the
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data suggest that a return of the habituation phenomenon in
mice may reflect in a repeated test design the recovery of
exploratory motor activity.
In the 5,6-0HT treated mice the catecholamines were
at normal levels on the lOth post-treatment day; it may be
inferred therefore that the occurrence of the habituation
phenomenon in 5,6-0HT treated mice may be a reflection of
the recovery of the catecholamines.

The lack of dependence

of the habituation response upon brain catecholamine level
was implied by the results in the repeated tests with 6-0HDA
treated mice.

The habituation response was observed as

early as the 5th post-treatment day and continued thereafter inspite of the greater depletion of catecholamines
in the 6-0HDA treated mice as opposed to the 5,6-0HT treated
mice.

Moreover, recovery of exploratory activity in 6-0HDA

treated mice also occurred early (on the 4th post-treatment
day), again inspite of low catecholamine levels.
Controversy surrounds the mechanism of the locomotor
depression induced by 6-0HDA or 5,6-0HT.

Some have suggest-

ed that the depression of locomotor activity by 6-0HDA was a
non-specific toxic effect {Taylor et al., 1970; Evetts and
Iversen, 1970; Scotti de Carolis et al., 1971).

There is

evidence for independence of locomotor depression from the
catecholamine depleting action of 6-0HDA; for instance, even
though

pretrea~~ent

with desipramine prevented the depletion
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of NE by 6-0HDA, it did not prevent the locomotor depression
induced by 6-0HDA (Scotti de Carolis et al., 1971).

How-

ever, the evidence presented was not completely convincing
since the levels of NE were determined but not those of DA.
Moreover, it has been previously reported that NE uptake
blockers such as protriptyline can spare the noradrenergic
terminals but not the dopaminergic terminals from destruction by 6-0HDA (Evetts and Iversen, 1970).

Thus, the be-

havioral depressant effects in the absence of NE depletion
may reflect normal NE levels and depleted DA levels; the
latter may,per se, depress locomotor behavior.

The role of

catecholamine depletion in the depression of locomotion was
also suggested by our own 5,6-0HT data, as 5,6-0HT induced
early catecholamine depletion and depression of locomotion.
Not only does controversy exist concerning the cause
of locomotor depression by 6-0HDA or 5,6-0HT but also concerning the nature of the recovery of exploratory locomotor
behavior.

Aside from the suggestion of recovery from non-

specific toxic effects it was suggested that supersensitiv• .
ity of postsynaptic dopamine receptors may account for the
recovery of locomotor behavior after 6-0HDA (Ungerstedt,
197la). Alternatively, it was suggested that other neurotransmitter systems may take over the functional role of the
destroyed systems and thereby maintain behavior (Longo,
1975) •

On the other hand, it is also conceivable that the
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recovery of spontaneous exploratory locomotion in rodents
after either 6-0HDA or 5,6-0HT treatments may be due to the
restoration of a functional catecholamine pool.

The latter

has been suggested as the mechanism for the behavioral recovery from 6-0HDA induced anorexia in rats (Zigmond and
Stricker, 1973).
Our data are relevant to the nature of the depression
as well as recovery of locomotor activity after 6-0HDA.

The

data indicate that L-DOPA stimulated the locomotor activity
of 6-0HDA

~reated

mice to a greater degree than that of the

vehicle treated mice as early as one day after 6-0HDA
(Figure 6); this was at the time when the spontaneous exploratory activity of 6-0HDA treated mice was markedly depressed.

Similarly, on the 4th and lOth days after 5,6-0HT

treatment, mice exhibited a supersensitivity to apomorphine;
on these days they also exhibited a depression of spontaneous locomotor activity.

Thus, while supersensitivity of DA

receptors was present it could not account for the recovery
of spontaneous locomotor activity which occurred several
days later.

As L-DOPA stimulated the locomotor activity of

6-0HDA treated mice to a greater extent than that of vehicle
treated mice, it appeared that 6-0HDA did not have a nonspecific toxic effect on the efferent pathways responsible
for locomotor behavior.

A pertinent suggestion was

that 6-0HDA induced a sensory deficit (Ljungberg and
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ungerstedt, 1976) •
As there does not appear to be deficit in the efferent locomotor pathway (cf. above) and in view of the
strong implication of the role of catecholamines in locomotor

beh~vior

from previous studies (cf. Introduction), a

catecholamine hypothesis for the recovery of exploratory behavior is still tenable if viewed in the following way.

The

neurotoxins, 6-0HDA and 5,6-0HT, induce a loss of a functional pool of catecholamines.

The loss of this functional

pool may be responsible for the initial depression of locomotion observed after each neurotoxin.

Furthermore, the re-

covery of the activity of this functional pool may parallel
the recovery of exploratory behavior and habituation phenomenon in mice which received either neurotoxin.

The effects

of the functional pool may be amplified by the existence of
a concomitant receptor supersensitivity.

Thus, our data ap-

pear to be consistent with the concepts of a catecholamine
involvement with locomotion and with that of a functional
catecholamine pool.

Further experiments are needed to sup-

port these postulated functional relationships involved in
recovery of locomotion which occurs in spite of prolonged
catecholamine depletion in 6-0HDA treated mice.
That the methamphetamine effect was reduced by 6-0HDA
pretreatment was not surprising, as amphetamines act at
least in part, via a presynaptic release of NE and DA (Moore

140
et al., 1970; Carlsson, 1970; Costa and Groppeti, 1970),
and as the stores of NE and DA were diminished in the 60HDA treated mice.

There was little or no recovery of this

effect throughout the test period in both the repeated and
single test procedure (Figures 4 and 5) , in agreement with
the prolonged effect of 6-0HDA on brain catecholamines
(Table 1) •

Similar results were obtained by others (Fibiger

et al., 1973; Creese and Iversen, 1974).
Soon after 5,6-0HT treatment, mice exhibited a reduced
response to methamphetamine.

This effect was observed in

the case of the single test procedure on the 1st

b~t

not on

the 4th post-treatment day, and through the 7th post-treatment day in the case of the repeated test.

In the repeated

test, the 5,6-0HT treated mice exhibited a trend of a gradually increasing response to methamphetamine after the initial inhibition observed on the 1st post-treatment day
(Figure 3).

The slow progressive trend may have reflected a

gradual return of the catecholamines to normal from their
depleted levels.

Normal catecholamine levels were observed

on the lOth post-treatment day.

After the initial dimin-

ished response to methamphetamine on the first day, the 5,60HT treated mice subsequently exhibited in the single test
procedure an increased locomotor response to methamphetamine
(Figure 4) •

This increased response to methamphetamine in

5,6-0HT treated animals may have reflected a loss of the in-
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hibitory serotonergic system which was postulated (Baldessarini et al., 1975; Creese and Iversen, 1974; Green and
Harvey, 1974; Mabry and Campbell, 1973, 1974; Mogilnicka et
al., 1977) to modulate catecholamine arousal in the rat; although the concept was questioned by Jacobs et al.

(1975a)

it was recently reconfirmed in rats by Breese et al.

(1974a) •

The absence of an enhanced response to methamphetamine in
6-0HDA treated animals whose 5-HT is depleted may have been
a result of the persistent marked depletion of NE and DA in
these mice.

Moreover, on the 20th day following 5,6-0HT

treatment the catecholamines but not 5-HT levels were restored
and there was an enhanced locomotor response to methamphetamine.

Thus, the present data support the concept of a sero-

tonergic inhibition of catecholamine mediated locomotion and
also of the presynaptic, indirect mechanism for the action
of methamphetamine.

PHARMACOLOGICAL ASSESSMENT OF CNS FUNCTION AFTER 6-0HDA OR
5,6-0HT TREATMENT

It was established that supersensitivity phenomena in
the periphery are associated with either the denervation or
disuse of synaptic junctions (cf. Introduction).

6-0HDA and

5,6-0HT were expected to chemically denervate and induce
disuse of central catecholaminergic and serotonergic path-
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ways, respectively.

Thus, the development of supersensi-

tive responses to central agonists was. considered in this
study to be indicative of the neuronal destruction induced
by 6-0HDA and 5,6-0HT.

It was expected that lesions of

serotonergic nerve terminals would induce a supersensitive
response to L-5-HTP, whereas lesions of dopaminergic nerve
terminals would induce supersensitive responses to apomorphine and L-DOPA.

Finally, lesions of cholinergic terminals

were expec.ted to induce a supersensitive response to the
centrally acting, cholinergic agonist, tremorine.
Some properties of supersensitivity phenomena in the
central nervous system may be expected to resemble these
phenomena in the periphery.

In the case of the loss of

central presynaptic nerve terminals, which possess active
high affinity neurotransmitter uptake mechanisms, it would
be expected that a rather specific supersensitive response
of the prejunctional type would develop.

As in the periph-

ery, the central prejunctional type of supersensitivity
would be expected to develop soon after the loss of the
neurotransmitter uptake process.

Moreover, a prejunctional

type of supersensitivity may be expected in the case of. central catecholaminergic, serotonergic and cholinergic neurons
all of which have well documented high affinity uptake
mechanisms (Iversen and Neal, 1968; Yamamura and Snyder,
1972).
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On the other hand, demonstration of the postsynaptic
type of supersensitivity in the central nervous system poses
several problems.

One problem is whether postsynaptic

supersensitivity of central receptors will exhibit the same
characteristics of non-specificity and delayed development
as exhibited by postjunctional supersensitivity in the periphery (cf. Introduction}.

Indeed, since central neurons

are sensitive to several neurotransmitters (Yarbrough and
Phillis, 1975} denervation or disuse of one neurotransmitter
input to a neuron may result in the development of supersensitivity to all of its other neurotransmitter inputs.

In

contrast, it is conceivable that postsynaptic supersensitivity of central receptors can be very specific in nature.
This question is difficult to answer because polysynaptic
pathways are involved in the ultimate expression of behavioral responses.

Therefore, it is difficult to demon-

strate that supersensitivity of only one neuronal pool is
responsible for the behavioral expression of supersensitivity.

Indeed, neurotoxin-induced alteration of a single re-

ceptor of a synapse constituting a link in a synaptic chain,
may initiate secondary changes in the other synaptic junctions of the chain which utilize different neurotransmitters.

These secondary compensatory changes may mimic non-

specific supersensitivity of the originally affected synaptic junction.
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Other methodological difficulties occur when one considers the possibility of the existence of isoreceptors.
For example, some investigators have postulated the existence of several different types of dopamine receptors.

DA

receptors have been characterized as being excitatory or inhibitory (Cools and Van Rossum, 1976) as well as presynaptic
and postsynaptic (Bunney and Aghajanian, 1975).

Thus, with

the possibility of the existence of several receptor subtypes the interpretation of the behavioral expressions of
neurotoxin-induced central receptor supersensitivity becomes
even more complex.

The following pages will describe the

responses of mice to several pharmacological agonists after
· 6-0HDA and 5,6-0HT treatments and relate them to the development of changes in receptor sensitivity.

CHOLINERGIC SYSTEM

Originally, it was suggested that the action of tremorine was indirect, via a stimulated synthesis and release
of ACh (Marchbanks, 1969}.

This hypothesis may need re-

vision (Cox and Potkonjak, 1969b).

Oxotremorine increased

the brain levels of acetylcholine in the rat (Cox and Potkonjak, 1969a) and cat (Pepeu et al., 1968); this is consistent with decreased ACh turnover.

In fact, oxotremorine

decreased ACh turnover (Trabucchi et al., 1975b) and ACh re-
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lease (Szerb and Somogyi, 1973).

Furthermore, a causal role

of increased ACh levels in tremor production following
tremorine was questioned since anticholinesterase agents
potentiated the increase in brain ACh but did not potentiate
the tremor (Cox and Potkonjak, 1969b).
such as propranolol,

reserpine,~-mpt

Furthermore, drugs
and

diethyldithiocar-

bamic acid were capable of inhibiting oxotremorine induced
tremor while they did not affect the increase in ACh levels
(Cox and Potkonjak, 1970).

On the other hand, tremor in-

duced by oxotremorine is readily blocked by atropine at
doses which did not prevent the increase in whole brain ACh
(Cox and Potkonjak, 1969b).

These recent data suggest that

tremorine after conversion to oxotremorine probably induces
tremor through a direct action on central muscarinic receptors (Cox and Potkonjak, 1969a,b) •
Tremorine also induces changes in the bioamines.

Do-

pamine levels were reported to increase after tremorine in
the rat, guinea pig and rabbit(Friedman et al.,l967}.

Fur-

thermore, brain stem levels of norepinephrine decreased and
those of serotonin increased (Friedman et al., 1963).

Re-

cently, the increase in 5-HT was correlated to the hypothermic action of tremorine (Cox and Potkonjak, 1967) ; the
latter investigators could not find any changes in the brain
DA content of tremorine treated rats.

The decrease in NE

was substantiated and found to be independent of tremorine's
hypothermic effect (Cox and Potkonjak, 1967).

A muscarinic
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mechanism was .suggested for the decrease in NE (Cox and
Potkonjak, 1967) •

Some role of NE in tremor production by

tremorine was implied since NE depleting agents and betaadrenergic blocking agents inhibit tremorine tremor (Cox
and Potkonjak, 1970; Leslie et al., 1972).

However, the

local anesthetic effects of beta-adrenergic blocking agents
or a non-specific depression of motor function with NE depleting agents may be responsible for the antagonism of
tremor (Cox and Potkonjak, 1970) .
The locus of tremor production appears to be with
the extrapyramidal motor system; the tremor may be initiated
in the neostriatum.

Tremorine and oxotremorine, its active

metabolite, induce tremor in a cerebellectomized preparation
(Everett, 1956) and in decerebrate animals (Everett et al.,
1956); mesencephalic tegmental lesions, however, inhibit
tremor induced by these drugs (Tasker and Kertesz, 1965).
Moreover, stereotaxic implantation of tremorine into either
globus pallidus, caudate nucleus and substantia nigra result
in tremor production (Cox and Potkonjak, 1969a) •

Similarly

intracaudate injections of another muscarinic cholinergic
agent carbachol also induced tremor (Connor et al., 1966).
Thus, an intact neostriata! and lower brain stem structures
are necessary for the expression of tremorine tremor.
Since 6-0HDA decreased DA and NE, it may be expected

that this depletion of catecholarnines would inhibit the

147
action of tremorine.

A similar inhibition of tremor might

be expected early after 5,6-0HT treatment when the catecholamines were depleted.
ed.

These expectations were not realiz-

On the 4th day following either 6-0HDA or 5,6-0HT

treatment, the tremorine responses were greatly exaggerated
{Table 8).

It should be emphasized that these exaggerated

responses were obtained in the absence of any significant
change in ACh levels whether in the 6-0HDA treated or in
5,6-0HT treated animals.

The exaggerated response to trem-

orine appeared to be longer lasting in the case of 5,6-0HT
treated mice since it was still evident on the 20th posttreatment day.

The particular sensitivity of the 5,6-0HT

treated animals to tremorine suggests that the phenomenon
may depend in part on the lesion of the serotonin containing
neurons, since on the 20th post-treatment day both the
levels of NE and DA had returned to normal levels and since
there was no evidence

of supersensitivity of catecholamine

receptors in these mice as evidenced by no enhanced response
to apomorphine or L-DOPA.

Tremorine increased central

levels of ACh (Holmstedt and Lundgren, 1966); which in turn
may induce increased 5-HT levels (Barnes et al., 1974) to
which the 5,6-0HT treated animals were shown to be supersensitive (cf. next section).

Altogether, the finding of an

exaggerated response to tremorine, in spite of lowered brain
levels of NE and DA in both 5,6-0HT and 6-0HDA treated mice
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on the 4th day (Table 8) , was surprising in light of the
expectations.
It may be suggested that 1) either the serotonergic
system supersensitivity is involved in the elaboration of
tremor following tremorine; indeed 5-HT but not NE or DA was
markedly depleted 20 days following 5,6-0HT treatment and
at that time the exaggerated response to tremorine was still
evident; 2) a hitherto undetected change in central choli-·
nergic function may have occurred following either 6-0HDA
or 5,6-0HT treatment.

SEROTONERGIC SYSTEM

L-5-HTP was used to stimulate postsynaptic serotonoceptive receptors and thereby assess their functional state.
5-HTP and high serum tryptophan levels increase the brain
content of 5-HT (Bogdanski et al., 1958J Fernstrom and
Wurtman, 1972); 5-HTP retained this ability after either
6-0HDA or 5,6-0HT treatment (Table 3).

Unfortunately, 5-HTP

is taken up by the neurons rather unspecifically and it may
displace endogenous stores of NE (Dahlstrom and Fuxe, 1964;
Corradi et al., 1967).

Tryptophan may be a more selective

precursor of 5-HT than is 5-HTP; this is evidenced by the
selective enhancement of the fluorescence of raphe terminals
{Aghajanian and Asher, 1971) and by increased brain 5-HT
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after tryptophan loading (Grahme-Smith, 1971).

However,

tryptophan may be inappropriate to test serotonoceptive receptor function since in the case of 5,6-0HT treatment a decrease in tryptophan hydroxylase has been observed and this
may limit the amount of conversion of L-tryptophan to 5-HT
(Victor et al., 1973 ; Lovenburg and Victor, 1974).

Fur-

thermore, it is not yet clear whether the observed increase
in brain indole fluorescence following tryptophan is due to
the accumulation of serotonin or, in addition, to other indolamines (Bjorklund et al., 1971).

Anden (1968) suggested

that 5-HTP stimulates serotonergic receptors as evidenced
by an enhancement of the hindlimb extensor reflex.

In ad-

dition, blockers of 5-HT uptake also enhance the hindlimb
extensor reflex by enhancing the amount of serotonin at the
synapse (Meek et al., 1970).

The extensor reflex was

utilized to demonstrate the destruction of serotonergic
terminals by 5,6-0HT (Daly et al., 1973); a combination of
drugs requiring the presynaptic integrity of 5-HT terminals
could no longer exert their influence on the reflex after
5,6-0HT treatment.
The tremorigenic response to 5-HTP was greatly increased throughout the testing period of 20 days in the
5,6-0HT and 6-0HDA treated mice.

The results of this inves-

tigation were the first description of central 5-HT receptor
supersensitivity (Barnes et al., 1973 a, c).

The phenomena
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of central 5-HT receptor supersensitivity has been recently
confirmed by others (Gerson and Baldessarini, 1975; Jacobs
et al., 1975b; Klawans et al., 1975; Longo et al., 1974;
Stewart et al., 1976).

The mechanism of this supersensitiv-

ity may be analogous to that hypothesized for the increased
sensitivity to L-DOPA of 6-0HDA treated animals (Barnes
et al., 1973b); while the latter may be due to the impairment of NE and/or DA uptake by the catecholamine nerve
terminals (Bell et al., 1970} or due to changes in postsynaptic NE and/or DA receptor sensitivities (Ungerstedt,
197la}, the increased sensitivity to 5-HTP in 5,6-0HT treated animals may be due to a lesion of the serotonergic neurons
(Baumgarten et al., 1973).

Thus, a lesion of serotonergic

terminals may result in an impairment of the 5-HT uptake by
serotonergic neurons and induce a presynaptic type of supersensitivity (Daly et al., 1973; cf. Introduction}.

There

may also be an increase in the sensitivity of the postsynaptic 5-HT receptor.

In a similar ve.in, the supersensi-

tivity to 5-HTP observed also in the case of 6-0HDA treated
animals may be related to a lesion of 5-HT containing
neurons which may be surmised on the basis of the long lasting depletion of 5-HT recorded in these animals (Table 1).
In fact, the question might be raised as to the significance of dopamine or norepinephrine depletion as possible
mechanisms for the enhancement of the 5-HTP response since
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these occurred in mice treated with either 6-0HDA or 5,60HT (Table 1).

However, a serotonergic involvement can be

suggested by examination of the tremor responses and neurochemical findings in mice on the 20th day after intracerebral injection of 5,6-0HT or 6-0HDA.

In the case of 6-0HDA,

5-HT was still depleted as were the catecholamines.

However,

in the case of 5,6-0HT treated mice only the levels of 5-HT
but not those of NE and DA were significantly depleted on the
20th day after intracerebral injection.

In fact, in view of

the results obtained with the DOPA test and apomorphine test
on the 20th day after 5,6-0HT (cf. next section) it could be
concluded that supersensitivity of catecholaminoceptive receptors was not present on that day.

Therefore, the en-

hanced response of 5,6-0HT treated mice to 5-HTP was most
probably related to a destruction of brain serotonergic
systems, and this mechanism probably accounts for the similar
findings in 6-0HDA treated mice.
It would be interesting to examine the possibility
that 5-HTP induced tremors may be induced by activation of
the inferior olive cells and the corresponding climbing
fiber input into the cerebellum (Llinas and Volkind, 1973)
similar to that induced by harmaline.

Such a mechanism

should help elucidate the 5-HT-DA mechanism involved in
Parkinsons disease, especially since it has not been possible to induce a Parkinsonism tremor in primates unless both
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striatal DA and 5-HT were lowered by a ventrotegmental
lesion (Poirier and Sourkes, 1976); this has cast some doubt
as to a purely dopaminergic etiology for the disease.

Ad-

mittedly, it is a frequent finding that both DA and 5-HT
are depleted in the Parkinsonism patient (Hornykiewicz, 1973
a,b).

It has been suggested that tremor results when the

dopaminergic system is impaired in animals with lesions in
the rubro-olivo-cerebellar pathway (Larochelle et al.,
1971}.

Obviously, additional research is needed to eluci-

date the physiological role of 5-HT and the other neurotransmitters in the extrapyramidal motor system.

CATECHOLAMINERGIC SYSTEM

The response of the 5,6-0HT treated animals to L-DOPA
should be compared with those of 6-0HDA treated animals
(Tables 5 and 7, Figure 6}.

Without DOPA treatment neither

group displayed aggression or hyperirritability as described
by Nakamura (1972} for 6-0HDA treated rats.

In confirmation

of the data of others (Ungerstedt,l97la; Uretsky and Schoenfeld, 1971} the 6-0HDA treated animals exhibited in our
hands an exaggerated response to L-DOPA, whether this response was evaluated by the Everett test (Everett, 1962,
1967} or in terms of changes in the locomotor activity after
L-DOPA.

In sharp contrast, the response to the L-DOPA
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challenge of the 5,6-0HT treated mice was not statistically
different from those of the controls whether in the case of
the Everett test or the locomotor activity test; this suggested a lack of pre.junctional type of dopamine receptor
supersensitivity in 5,6-0HT treated mice.

Longo et al.

(1974) reported with the Everett test a transient increase
in response to L-DOPA after 5,6-0HT.

However, they did not

evaluate their data statistically.
Some dopaminergic supersensitivity of the postjunctional type was evident in 5,6-0HT as well as 6-0HDA treated
mice, because both groups exhibited enhanced responses to
apomorphine.

An enhanced response to apomorphine is gen-

erally interpreted as the phenomenon of postsynaptic DA
receptor supersensitivity (Ungerstedt, 197la) •

The response

to apomorphine of 5,6-0HT treated mice was less than that
of 6-0HDA treated mice.

The enhanced response to apomor-

phine was of a transient nature in 5,6-0HT treated mice
while it persisted in the 6-0HDA treated mice.

It should be

emphasized that the response to apomorphine, besides its
well recognized effect on the DA receptor (Ernst, 1969) , may
also depend in part on the state of the serotonergic neurons
(Grabowska et al., 1974).

Altogether, these data are con•

sistent with the concept that the supersensitivity to L-DOPA
and apomorphine is due to the nerve terminal lesion induced
by 6-0HDA, as well as with the notion that the action of the
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latter, just as that of 5,6-0HT is only relatively specific.
The interaction of central noradrenergic and dopaminergic receptors proposed by some investigators {Nyback et
al., 1970; Consolo et al., 1975; Anden and Strombom, 1974)
may have relevance to the lack of an enhanced response of
5,6-0HT treated mice to L-DOPA.

For example, Stromberg and

Svensson {1971) suggested that the L-DOPA induced hyperactivity in mice required both DA and NE receptor stimulation.

The lack of a marked supersensitivity of 5,6-0HT

treated mice to L-DOPA may suggest that the postulated noradrenergic-dopaminergic interaction was not altered in the
same way by 5,6-0HT and 6-0HDA.

SEVERAL COMMENTS ON THE NATURE OF CNS SUPERSENSITIVITY

One might conclude that a decentralization type {cf.
Introduction) of supersensitivity developed in the CNS following both 5,6-0HT and 6-0HDA.

The decentralization con-

cept was implied by the results concerned with the cholinergic system.

6-0HDA and 5,6-0HT did not reduce brain ACh

levels, suggesting that neither agent destroyed cholinergic
neurons.

However, both agents induced a supersensitivity to

the cholinomimetic, tremorine.

Thus, one might conclude

that the cells containing the catecholamine and serotonin
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receptors became supersensitive to the muscarinic agent, and
that the supersensitivity induced, was similar to the nonspecific decentralization type of supersensitivity that occurs in the periphery.

Furthermore, as 6-0HDA induced a

supersensitivity to L-5-HTP and as 5,6-0HT induced a supersensitivity to apomorphine these findings also suggested
that a non-specific decentralization type of postsynaptic
supersensitivity developed.

Moreover, a 6-0HDA induced

decentralization type of supersensitivity of DA receptors
was suggested by others (Costall and Naylor, 1976).

How-

ever, the results of Costall and Naylor (1976) are difficult to interpret as they could not demonstrate a supersensitivity to dopamine in the same preparations that exhibited
the "non-specific supersensitivity" to NE and 5-HT.

This

discrepancy casts doubt as to the utility of the method
which they employed to demonstrate non-specific supersensitivity.
In contrast, careful review of our data suggests an
alternative hypothesis to the concept of a decentralization
type of CNS receptor supersensitivity.

The data suggest the

existence of the phenomena of specific postsynaptic receptor
supersensitivity in the CNS.

6-0HDA induced a prolonged

depletion of brain 5-HT; this suggests that 6-0HDA induced a
lesion of 5-HT neurons.

Thus the fact that 6-0HDA treatment

induced a supersensitivity to L-5-HTP is consistent with the
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concept of a specific 5-HT receptor supersensitivity that is
secondary to a lesion of serotonergic neurons.

Similarly,

the fact that 5,6-0HT treatment induced a supersensitivity
to apomorphine is consistent with the development of specific DA receptor supersensitivity that is secondary to a lesion of DA

neurons~indeed,

a 5,6-0HT induced lesion of dopa-

minergic neurons is suggested by the depletion of brain DA
induced by this agent.

Furthermore, the fact that after

5,6-0HT, both the depletion of brain DA and the supersensitivity to apomorphine were reversible suggested that these
two phenomena were related.

Furthermore, both the 5,6-0HT

induced depletion of 5-HT as well as the supersensitivity to
L-5-HTP were long lasting and these findings suggest that
these phenomena were related.

Lastly, both the 6-0HDA in-

duced depletion of DA as well as the supersensitivity to
apomorphine were long lasting and these findings suggest
that both of these phenomena were related.

All these data

emphasize the important concept that supersensitivity
phenomena are correlated closely in time with neuronal destruction (i.e. neurotransmitter depletion).
When receptors are in a state of decentralization
supersensitivity, they simultaneously exhibit supersensitive
responses to a variety of agonists (Sharpless, 1975).

Thus,

if 6-0HDA induced a state of decentralization supersensitivity of either DA or 5-HT receptors these receptors would
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exhibit simultaneous supersensitive responses to apomorphine,
L-5-HTP and to tremorine.

However, the 6-0HDA treated mice

exhibited supersensitive responses to dopamimetics and L-5HTP for up to 20 days but to tremorine only up to the 4th
day after treatment.

Thus, a primary characteristic of non-

specific decentralization supersensitivity has not been fulfilled, as the mice were not simultaneously supersensitive to
apomorphine and tremorine or L-5-HTP on all of the days
tested.

Altogether, it appears that the 6-0HDA induced

short term alteration of the cholinergic system can not be
correlated with a lesion of cholinergic neurons (i.e. no ACh
depletion) nor with a long term induction of supersensitivity of DA and 5-HT receptors.

Thus, the data suggest that

the supersensitivity to tremorine may be related to other
phenomena.
Altogether, the data support a concept of specific
rather than non-specific postsynaptic receptor supersensitivity in the CNS.

Thus, other mechanisms must be postulat-

ed to account for the enhanced response to tremorine.

For

example, if tremorine's action is dependent in part upon ACh
release as suggested by Pepeu et al. (1974b), a 6-0HDA induced
loss of striatal acetylcholinesterase activity may result in
an apparent supersensitivity to tremorine.

This latter con-

cept as well as the alternative hypotheses of neurotoxin induced changes in cholinergic-dopaminergic or cholinergicserotonergic neuronal interactions (cf. previous
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Discussion) may be involved in the tremorine response.
Lastly, the induction of secondary compensatory changes
within synaptic chains may also be a more likely explanation
than to hypothesize the non-specific decentralization type
of supersensitivity as an explanation for the tremorine responses.
In summary, the data obtained suggest that a lesion of
catecholamine neurons induced a supersensitivity to catecholaminergic agonists.

Furthermore, a lesion of serotonergic

neurons induced a supersensitive response to serotonergic
agonists.

Thus, a specific supersensitivity developed in

the case of serotonergic and catecholaminergic neurons.

The

analogous case in the periphery is the prejunctional type of
supersensitivity where the supersensitivity is specific in
nature.

In fact, the data suggest the development of both

a prejunctional (L-DOPA) as well as a postjunctional (apomorphine) type of supersensitivity of dopaminergic receptors.

In the case of the 5-HTP response a prejunctional as

well as postjunctional supersensitivity of serotonergic receptors could also have developed.

Therefore, the data sug-

gest an important concept: the possibility that the postjunctional form of supersensitivity of central catecholamine
and serotonergic receptors is specific in nature, as opposed
to non-specific in nature as it exists in the periphery.
fact, recent microiontophoretic studies also support the

In
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concept of specific postsynaptic

receptor supersensitivity

in the CNS, as 6-0HDA treatment enhanced the response of
striatal cells to DA but not to 5-HT or NE (Yarbrough and
Phillis, 1975).

Admittedly, a great deal of additional

research would be required to resolve this complex and important issue.
One may hypothesize that a specific postsynaptic
supersensitive response may indicate that dopaminoceptive
and serotonoceptive striatal cells receive only one physiological transmitter input, dopamine or serotonin, respectively.

Thus, postsynaptic cells may develop a supersensi-

tive response to their physiological transmitter because
they lack receptors for other neurotransmitters.

This

speculation,however, is not tenable in light of the demonstration of the receptiveness to both 5-HT and DA by stria•
tal cells (Yarbrough and Phillis, 1975).
Therefore, it is suggested that neurons of the CNS may
develop a differential supersensitive response.

Thus, when

hypofunction occurs in only one neurotransmitter input, the
postsynaptic neuron may respond by developing a postsynaptic
supersensitive response to only that neurotransmitter which
is deficient.

Admittedly, such a corollary to Dale's prin-

ciple may be very speculative and much additional experimentation would be required to substantiate such a phenomenon.
However, the possibility of the presence of both a specific
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postsynaptic as well as a specific prejunctional type of
supersensitivity in the CNS represents a very elegant
mechanism for maintenance of brain function within normal
limits.
Presynaptic as well as postsynaptic mechanisms of
supersensitivity, as well as the recovery of functional
pools may all be important in maintaining or restoring brain
function.

One can see from the results presented

that even

after "behavioral recovery" an abnormal state may still be
present; such a state can be reflected by pharmacological
hypofunction (subsensitivity) or hyperfunction (supersensitivity).

Thus, 6-0HDA decreased amphetamine's action as the

latter depends on the presynaptic store of catecholamines.
Similarly, 5,6-0HT induced a subsensitivity to the facilitation by chlorimipramine of the hindlimb extensor reflex.
which depends upon a presynaptic supply of 5-HT in the
spinal cord (Daly et al., 1973).

On the other hand, 6-0HDA

and 5,6-0HT induce supersensitivity to apomorphine and L-5HTP respectively.

Thus, a pharmacological presynaptic sub-

sensitivity may exist concomitantly with a

postsynaptic

pharmacologic supersensitivity while a minimal functional
pool may be maintaining behavior within normal limits.
The finding of supersensitivity in the catecholaminergic systems is not a new concept, hut the employment of
neurotoxins to induce this supersensitivity is n0vel.
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Previously, supersensitivity has been demonstrated in the
central catecholaminergic systems following: chronic reser-

pine treatment (Stolk and Rech, 1967; Rech and Stolk, 1970),
axotomy (Trandelenburg, 1966) or the inhibition of catecholamine synthesis (Dominic and Moore, 1969).

Furthermore,

recent research suggests that the sensitivity of catecholamine receptor may be altered by hormonal influences (Emlen
et al., 1972; Engstrom et al., 1974; Huidobro-Toro et al.,
19 74) •
The conclusion that the 5-HTP and L-DOPA supersensitivity in the 5,6-0HT and 6-0HDA treated mice, respectively,
is dependent upon the ultimate synthesis of the normal
neurotransmitters, is evidenced by the fact that at effective doses, the decarboxylase inhibitor, RO 4-4602, completely blocked the 5-HTP as well as the L-DOPA response.
It appears that the catecholamines and 5-HT rather than
their precursors, are responsible for the responses to the
L-DOPA and 5-HTP challenge, respectively, and that when the
formation of the bioamines is prevented by the decarboxylase
inhibitor (Pletscher and Bartholini, 1971; Hyttel et al.,
1972) the response to the precursor is blocked.

Furthermore

it is of interest that at low doses, RO 4-4602 potentiated
the central while attenuating the peripheral actions of 5HTP.

This is consistent with the fact that at these low

doses RO 4-4602 blocks decarboxylase peripherally but not
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centrally (Pletscher and Bartholini, 1971), thus increasing
the availability of 5-HTP to the CNS.

SUMMARY

The results of this study indicate no specificity and
a relative rather then an absolute selectivity for both
agents.

In the case of 6-0HDA a specific lesion of the

catecholamine system was expected and the following findings
supported such a contention: a) NE and DA were depleted for
a long time period; b) the responses to L-DOPA or apomorphine were exaggerated over the same time period whether
evaluated in terms of the locomotor activity, the Everett
test or finally by observation; c) the response to amphetamine was decreased throughout the study; d) the brain content of ACh was not affected.

However, a case for non-

specificity of the action of 6-0HDA may also be made: a)
brain 5-HT was depleted throughout the study; b) the response to L-5-HTP was exaggerated throughout the study;
c) transient changes in cholinergic function were observed
as evidenced by an enhanced tremorigenic effect to
tremorine on the fourth post-treatment day.
Similarly, in the case of 5,6-0HT a specific lesion of
the indolamine system was expected.

The following experi-

mental results suggest that the expectation was realized:
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a) long lasting depletion of brain 5-HT; b) long lasting
exaggerated responses to L-5-HTP; c) a lack of effect on ACh
content.

However, a case for non-specificity of 5,6-0HT may

also be made since transient decreases in brain NE and DA
were observed up to the lOth post-treatment day and an enhanced response to apomorphine existed to the lOth posttreatment day.

Finally, the tremor response to tremorine

was increased for some time implying either a serotonergic
mechanism, a cholinergic-serotonergic interaction, or a biochemically undetected change in the function of the cholinergic system was induced by 5,6-0HT treatment.
The results of this study emphasize the multitransmitter phenomena involved in the actions of 6-0HDA and
5,6-0HT, as well as the concomitant complexities of their
effects on drug responses and on behavioral paradigms.

A

relatively selective lesion of indolamine neurons may be an
achievable goal with 5,6-0HT if sufficient time is allowed
for the restoration of NE and DA levels following their
initial depletion.

However, without concomitant morphologi-

cal or kinetic studies such a selectivity may only be suggested by the present data.

Furthermore, it is interesting

to note that although behavioral recovery may be manifested
following these neurotoxic agents (i.e. normal locomotive
behavior) , there may remain a "pharmacodynamic alteration"
(i.e. hypersensitivity or subsensitivity).

Such lasting
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pharmacological alterations may be exploited by the
judicious use of agonist agents such as apomorphine, L-5~TP

and tremorine as neuropsychodiagnostic tools to help

elucidate the nature of neuropathology whether in the case
of emotive, cognitive or neurological involvements.

Such

an approach may be desirable to help identify the etiologies
of dyfunctions which may result in common behavioral expressions such as the schizoid states, depressions and
choreas.

Obviously, different behavioral substrates may

have different susceptibilities to both impairment and recovery and each needs to be evaluated individually in that
regard.
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